UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
FOR ANNUAL AND TRANSITION REPORTS
PURSUANT TO SECTIONS 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Mark One)
[X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the year ended December 31, 2004 or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from ________ to ________.
Commission file Number 0-6333
HYDRON TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
New York 13-1574215
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2201 West Sample Road, Building 9, Suite 7B, Pompano Beach, FL 33073
-------------------------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (954) 861-6400
--------------
Securities registered pursuant to Section 12(b) of the Act: None
----
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
--------------------------------------
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. YES [X] NO [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein and will not be contained, to the
best of the Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any other
amendment to this Form 10-K. [ ]
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2). YES [ ] NO [X]
The aggregate market value of the voting stock held by non-affiliates of
the Registrant was $1,226,087 based upon the closing price of $0.18 on March 28,
2005.
Number of shares of Common Stock outstanding as of March 28, 2005:
9,310,336.
Documents Incorporated by Reference: None
1
TABLE OF CONTENTS PAGE
Part I
Item 1. Business 3
Item 2. Properties 12
Item 3. Legal Proceedings 12
Item 4. Submission of Matters to a Vote of Security Holders 13
Part II
Item 5. Market for Registrants Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities 14
Item 6. Selected Financial Data 18
Item 7. Management's Discussions and Analysis of Financial
Condition and Results of Operations 18
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 31
Item 8. Financial Statements and Supplemental Data 31
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure 31
Item 9A. Controls and Procedures 31
Part III
Item 10. Directors and Executive Officers of the Registrant
33
Item 11. Executive Compensation 34
Item 12. Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters 37
Item 13. Certain Relationships and Related Transactions 38
Part IV
Item 14. Principal Accountant Fees and Services 39
Item 15. Exhibits, Financial Statement Schedules and Reports
on Form 8-K 39
Report of Independent Certified Public Accountants 42
Financial Statements: Balance Sheets - December 31, 2004 and 2003 43
Statements of Operations
Years ended December 31, 2004, 2003, and 2002 44
Statements of Changes in Shareholders'
Equity for the Years ended December 31, 2004, 2003, and 2002 45
Statements of Cash Flow
Years ended December 31 2004 2003,and 2002 46
Notes to Financial Statements 47
Signatures 61
Exhibit Index 62
Certification of Chief Officers Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 and Item 307 of Regulation S-K 63
Certification Pursuant to 18 U.S.C., Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 66
2
Item 1. Business
Introduction
Hydron Technologies, Inc. ("the Company"), a New York corporation
organized on January 30, 1948, maintains its principal office at 2201 West
Sample Road, Building 9, Suite 7B, Pompano Beach, Florida 33073 and its
telephone number is (954) 861-6400.
Hydron Technologies, Inc. is conducting research and development into
products and medical applications utilizing its patented tissue oxygenation
technology. The Company's super-oxygenation technology delivers pure oxygen
through the skin to tissue depths considered therapeutic for wound healing and
the maintenance of tissue viability. Hydron's technology utilizes micro-bubbles,
averaging one micron in diameter, to deliver oxygen deep into tissue. Applied
topically, oxygen can now be targeted at specific problem areas and delivered
into skin and tissue that is not receiving sufficient oxygen from the
bloodstream, essentially oxygenating from the outside in.
The Company also markets a broad range of cosmetic and oral health care
products using a moisture-attracting ingredient (the "Hydron(R) polymer") and a
topical delivery system for active ingredients including pharmaceuticals. The
Company holds U.S. and international patents on, what Management believes is,
the only known cosmetically acceptable method to suspend the Hydron polymer in a
stable emulsion for use in personal care/cosmetic products. The Company is
developing other personal care/cosmetic products for consumers using its
patented technology and would, when appropriate, either seek licensing
arrangements with third parties, or develop and market proprietary products
through its own efforts. Management believes that because of their unique
properties, products that utilize the Hydron polymer have the potential for wide
acceptance in consumer and professional health care markets.
Liquidity
The Company anticipates that present working capital balances and
internally generated funds will be sufficient to meet our working capital needs
for the next three months and maybe longer based on management decisions and
order flow. Beyond that point, it will be necessary to consummate a merger, sell
selected assets, or obtain an infusion of capital. The Company's independent
accountants issued a "going concern" opinion since the Company has incurred
significant losses over the past five years and generates a negative cash flow
on a monthly basis.
On January 28, 2005, the Company entered into a marketing agreement to
license its technology with Clinical Results, Inc., and the Hydron branded
products with Bioceutical Research, Inc. Any impact on cash flow is not expected
to be realized for six to nine months. In addition, the Company has lowered its
operating expenses by reducing research and development costs and reducing
payroll costs.
3
Item 1. Business (continued)
The Company is considering several additional options to resolve the
negative cash flow, including merging with parties that have a broad channel of
distribution, forming a new private entity and transferring the operating assets
to it and selling the public shell, and selling one or more selected assets. One
of these alternatives and/or an infusion of additional capital will be required
in order to generate the cash required in the short term.
Super-oxygenated Fluids and Compositions
Since August 2000, the Company has been researching and developing a new
technology that provides a method for the delivery of oxygen into the skin and
tissue at depths considered medically therapeutic. In November 2003, the Company
received patent number 6,649,145 from the United States Patent and Trademark
Office covering this exceptional method of delivery; which bypasses the
bloodstream. Management anticipates that as a result of its continuing research
into tissue oxygenation, the Company's primary focus will be
developing/licensing applications or products based upon this new technology.
Hydron's unique process utilizes an existing technology that infuses
liquid with oxygen at 20+ times normal levels to create a super-oxygenated
liquid filled with micro-bubbles of highly pressurized oxygen. When placed in
contact with the skin, the highly saturated fluid and micro-bubbles are
transferred directly into the skin through osmosis and kinetic diffusion between
cells.
Research and development efforts to date have included clinical testing,
in-vitro bacteriological testing, micro-bubble size analysis, packaging
prototypes, and stability testing. Following its successful pre-clinical test at
the University of Massachusetts Medical School, Department of Thoracic Surgery,
the Company commissioned a clinical test on healthy human subjects. This
clinical test produced an average increase in subcutaneous tissue oxygenation of
54%. Management believes that these tests provided the first-ever evidence that
subcutaneous tissue could be oxygenated from the outside in without the use of
high pressure-chamber treatment.
This topically applied oxygenated skin treatment could have numerous
applications in wound healing and anti-aging skincare treatments. Although it is
unknown at this stage the significance that topically applied oxygenated skin
treatment would have on the various categories, there are a large number of
people with oxygen deprived ailments. Current market research shows that each
year, in the United States alone, medical problems associated with oxygen
deprivation of the skin and tissues can affect diabetics, burn patients,
individuals with impaired circulatory systems, those suffering from chronic
wounds, even the viability of organs being transported for transplantation.
Likewise, medical problems associated with anaerobic bacteria (i.e. organisms
that thrive in the absence of oxygen) such as acne, diaper rash, post-operative
infections, and periodontal disease may be reduced or eliminated by application
of this technology.
4
Item 1. Business (continued)
Oxygen is also an essential factor in aging as facial skin loses about 40%
of its oxygen carrying capacity by age 65 (a factor in diminished collagen
formulation and wrinkling). As a result, anti-aging/wrinkling applications of
this technology may ultimately lead to a new line of skincare treatments and
products.
In July 2002, the Company reached an agreement providing it the right but
not the obligation to license existing micro-bubble machine technology from Life
International Products, Inc. that included issuance of 325,000 shares of Hydron
stock and future royalty payments to Life International should the Company use
its technology. This agreement provides Hydron with a definitive means to
produce micro-bubble liquids that are required to manufacture future products
under Hydron's tissue oxygenation patent.
On November 14, 2003, the Company completed a non-brokered private
placement to accredited investors of 2,210,000 Units at $.50 per Unit that
raised $1,105,000 for oxygenation technology research. Each Unit is comprised of
one share of Common Stock and one five-year warrant to buy one additional Common
Share at $1.00. Such securities were not registered under the Securities Act of
1933 as amended ("Securities Act"), in reliance on exemptions for private
placements of securities. Directors Richard Banakus and Ronald J. Saul invested
in this offering along with 17 other accredited investors. The proceeds will be
used to advance the testing and development of the Company's oxygenation
technology and support the initial submissions required for FDA (Food and Drug
Administration) approvals.
A formal Request For Designation (RFD) was filed with FDA in September
2004 to request that FDA designate the MicroO2 Oxygenation Apparatus as a
medical device. FDA agreed in October. On January 10, 2005, the Company attended
a Pre-Investigational Device Exemption meeting with FDA to present the device,
however, a clear pathway for safety and clinical research requirements could not
be determined at that time. It was suggested that filing a complete 510(k)
application would provide FDA with an opportunity to review additional
information from Hydron.
Hydron(R) Branded Skin Care Products
The Company has been developing various consumer products using Hydron
polymers since 1986. The Company's products are designed to address concerns
about aging, and include Hydron(R) skincare, hair care, bath and body and sun
care lines. The Company currently has thirty-six individual products available
in the following product catagories: skin care (21 products), hair care (6
products), bath and body (7 products) and sun care (2 products). These products
are also packaged into collections and sold at a more favorable value than the
individual products sold separately. All of the products are available through
the Hydron catalog and web site at www.hydron.com ("Catalog").
Management believes that the Company's moisturizers and skin treatments
are unique and offer the following competitive benefits: they self-adjust to
match the skin's optimal pH balance soon after they are applied to the skin;
they become water-insoluble on the skin's surface, and unlike all other
water-based cremes and lotions, are not removed by the skin's perspiration or
plain water; they are oxygen-permeable, allowing the skin to breathe; they do
not emulsify the skin's natural moisturizing agents, as do conventional cremes
and lotions; and they attract and hold water, creating a cushion of moisture on
the skin's surface that promotes penetration of other beneficial product
ingredients, all while leaving no greasy after-feel.
5
Item 1. Business (continued)
The Company's products are independently tested by dermatologist and, in
their opinion, are considered to be safe, non-irritating and applicable to most
skin types. Products for use around the eye area are also ophthalmologist tested
and safe for contact lens wearers. Most of the Company's moisturizing products
are based on the Company's patented emulsion system, which permits the product
ingredients to deliver their intended benefits over an extended period of time
and in a more efficient manner.
Management believes that the Hydron(R) emulsion system can enhance the
effectiveness of topical over-the-counter medications. The emulsion system is
designed to deposit a polymer film on the skin's surface which has a number of
advantages over traditional lotions: it promotes hydration of the outer layer of
skin, improves penetration into the skin's pores, and has good tactility and
flexibility. The Company expects to continue to focus research and development
resources on proprietary technology-based products as determined by Management's
assessment of consumer demand.
The Company discovered that the Hydron emulsion system also adjusts pH on
the skin to match the pH of the stratum corneum, the skin's surface layer. The
pH range of the emulsion system is ideal for promoting the skin's natural
healing process and enzyme production responsible for rebuilding the skin's
lipid barrier. A patent application was filed February 14, 2002 to cover this
technology, which also applies to a new acne treatment system.
Professional Products
The Company has also developed and currently markets a group of Hydron
polymer-based products for dental professionals under the Hydrocryl(R) brand
name. These include a heat cured material used in the manufacture of dentures,
as well as cold cure kits used in connection with the relining or repairing of
existing Hydrocryl or conventional acrylic dentures that is necessitated by the
continual changes that occur in the tissue structure of the mouth. Management
believes that the hydrophilic, or moisture attracting properties, of these
Hydron(R) polymer-based products give them competitive advantages over
conventional acrylic dentures and denture repair kits, which are not
hydrophilic. Sales of Hydrocryl(R) brand name products were minimal in 2004,
2003, and 2002.
Distribution
The majority of the Company's products are currently sold in the United
States through Hydron direct marketing channels (proprietary Catalog and the
World Wide Web site). The Company also sells its products to private label
customers, television retailers and, to a lesser extent, internationally through
salons and doctors offices.
6
Item 1. Business (continued)
While in prior years television retail was the primary focus for the
marketing and distribution of the Company's products, Management believes that
the Company's exclusive agreements with television retailers had limited the
marketing opportunities to build its business through additional sales channels.
Under exclusive contracts with television retailers the Company neither
controlled its airtime nor the selling priorities of those television retailers,
effectively handicapping the Company's ability to influence sales trends.
The Company began diversifying away from television retailers in 2001 with
continued focus on developing the Catalog business and the addition of a private
label customer to provide additional cash flow. Further, the Company has been
pursuing new international distribution and new products that would
significantly augment Hydron's direct marketing efforts. This development
includes filing a patent in February 2002 on new acne formulas that the Company
believes provides marked performance improvements versus other over-the-counter
products currently on the market.
Catalog Sales - The Company's full color brochure offers personal care products
for sale directly to consumers. The brochure also provides information on new
products, educates consumers on proper skin care and facilitates consumer
re-ordering. The Company sells its products on the World Wide Web and regularly
transmits E-mail broadcasts to its customer base. Catalog sales represents
approximately 69.1% of Hydron's total annual sales in 2004 and 80.5% in 2003.
The Company is continuing to explore new ways to enhance Catalog sales and
operations.
Private Label Contracting - Effective March 1, 2001, the Company entered into an
agreement with Reliv International, Inc ("Reliv") to develop and manufacture a
line of private label skin care products under their brand name, ReversAge(R).
Reliv is a public company traded on NASDAQ (symbol RELV). Private label sales
represented approximately 19.2% of Hydron's total annual sales in 2004 and 4.7%
in 2003.
International - The Company sells products to an Australia-based health and
beauty products distributor for retail sale in salon stores and medical offices
in Australia and New Zealand. The Company also distributes dental products in
Spain and, to a lesser extent, other countries. Although this category is not
significant at this time, Management believes that it will expand with the
introduction of the Company's super-oxygenated technology.
Retail - The Company has established minor levels of retail distribution.
Initially, utilizing excess inventory, the Company has sold product on a
limited, promotional basis to several retailers utilizing current packaging
configurations. It is anticipated that any significant retail effort of core
Hydron products would require investment in repackaging.
Licensing - Effective January 28, 2005, the Company entered into a non-exclusive
licensing agreement with Clinical Results, Inc. ("CRI"), which allows for
certain Hydron cosmetic skincare product technologies sold and manufactured by
CRI, to be offered to third parties under private label contracts. Payment to
Hydron includes royalties based on wholesale sales by CRI to its customers. The
cosmetic technologies include the patented Hydron polymer and sunscreen
technology, patented line smoothing technology and patent-pending emulsifier
technology.
7
Item 1. Business (continued)
Effective January 28, 2005 Hydron has licensed Bioceutical Research, Inc.
("BRI") the non-exclusive right to market Hydron and Hydronamins branded
products to retail accounts, including drug stores, mass-merchandisers, club
stores, and salon/spa accounts. BRI will pay Hydron royalties on wholesale sales
while undertaking responsibility for manufacturing, marketing, and sales.
Research and Development
During the last two years, the Company's research and development efforts
advanced groundbreaking research into oxygenated wound treatments, healing
enhancement, and skin care that may provide anti-aging treatments. Where
possible, the Company may license these technologies to other companies with
expertise in specific applications of the Company's super-oxygenated technology.
Research and development efforts include product formulation, clinical testing,
packaging design and prototypes, extensive product safety and stability testing
conducted by medical professionals, efficacy studies to support product claims,
and consumer research.
The Company continues to concentrate research and development on
additional Hydron(R) super-oxygenated products, as well as on other proprietary
technology-based products as determined by Management's assessment of consumer
demand. The Company's research and development efforts during 2004 focused on
accumulating data for Food and Drug Administration (FDA) application for the
Company's oxygenation application.
Management has completed development of an acne ingredient delivery
system. The technology allows for acidic ingredients to be delivered to the
skin's stratum corneum at neutral pH (~6.8 to 7.0) where it then gradually
adjusts to match the pH of the stratum corneum below 5.5. This delivery
technique avoids the irritation and burning associated with traditional acne
treatments that deliver ingredients at pH values as low as 2.0. The Company has
patents pending on this technology in the US and major international markets.
In the current acne market, medicinal treatments can often be more
irritating and elicits more redness than the skin condition itself. The
Company's new system significantly reduces the harshness and irritation
associated with such products.
Charles Fox, a consultant and a former member of the Company's Board of
Directors from September 1997 to October 1998, leads the Company's research and
development efforts. Mr. Fox was formerly director of product development for
Warner Lambert Company's personal products division and was a former president
of the Society of Cosmetic Chemists.
Patented Technology
8
Item 1. Business (continued)
The Company strongly believes that technology and patent protection are
essential to providing a sound foundation for a new product. The Company was
granted a U.S. patent on its new super-oxygenation technology in November 2003.
This patent covers the process of applying a liquid containing pure oxygen
micro-bubbles to the surface of the skin such that the oxygen penetrates the
skin and oxygenates the underlying tissue. The Company has applied for
international patents in approximately 29 countries, which are in various stages
of review as of December 31, 2004. The Company expects these patent applications
to be approved over the next 12 months.
The Company was granted U.S. Patent No. 4,883,659, dated November 28,
1989, and U.S. Patent No. 5,039,516, dated August 13, 1991, which cover a stable
moisturizing emulsion containing an unusual emulsifying agent, as well as the
Hydron polymer and a unique combination of ingredients. These patents have
expiration dates of November 28, 2006 and August 13, 2008, respectively. During
1999 the Company was granted U.S. Patent No. 5,879,684 for its "Line Smoothing
Complex" formula. This product has been clinically shown to reduce fine lines
and wrinkles. The patent has an expiration date of April 11, 2017. In addition,
the Company has registered several trademarks relating to its cosmetic products.
The Company has also received patent protection for its emulsification
process in several countries to facilitate distribution and sale of these
products outside of the United States. The Hydron polymer, utilized in cosmetic
emulsions, creates a thin moisture-attracting film that is non-greasy; is not
dissolved by sebaceous oils or perspiration; does not emulsify the skin's
natural oils and humectants; and allows the skin to breathe. The film is
insoluble in water and resistant to rub-off, but can easily be removed with
cleanser and water.
The Company subsequently discovered that the Hydron emulsion system also
adjusts pH on the skin to match the pH of the stratum corneum, the skin's
surface layer. It is evident in recent skin research that the pH range of the
emulsion system is essential in contributing to the skin's natural healing
process and the enzyme production responsible for rebuilding the skin's lipid
barrier. The Company filed a patent application related to acid based ingredient
delivery, including acne ingredients, in February 2003. The application is
pending.
Manufacturing and Raw Materials
Hydron polymer-based products are manufactured exclusively for the Company
by independent third parties. The Company has used principally two manufacturers
of cosmetic products because of the quality of their production and reasonable
costs. To date, contract manufacturing has allowed the Company to meet inventory
requirements in a timely manner. All raw material and packaging components for
the Company's consumer and professional product lines are readily available to
the Company from a variety of sources.
The Company is not dependent upon any sole manufacturer or supplier for
any of its raw materials or ingredients.
9
Item 1. Business (continued)
Agreement with GP Strategies Corporation
Under the terms of an agreement with GP Strategies Corporation ("GPS"),
the Company has an exclusive worldwide license to manufacture, market or use
non-prescription products that include the Hydron polymer in the consumer field,
including in connection with cosmetic products and certain personal care
products, and in the oral health field, including dentures. Under the GPS
Agreement, GPS retains the exclusive right to manufacture, sell or distribute
any prescription drug or medical device made with the Hydron polymer, other than
in the oral health field. In addition, under the GPS Agreement, the Company and
GPS may each manufacture, sell, and use non-prescription drug products that
include the Hydron polymer as an active ingredient, that are not included in
their respective exclusive fields.
Under the GPS Agreement, GPS also licenses to the Company the trademark
Hydron for use in connection with the manufacture, marketing and use of products
using Hydron polymers as permitted under the GPS Agreement.
Under the terms of the GPS Agreement, the Company and GPS are each
required to pay to the other a royalty of five percent (5%) of their respective
net sales of Hydron polymer products, except for sales of certain specified
non-prescription drug products utilizing the Hydron polymer as an active
ingredient to third parties. Where the seller receives an up-front license fee,
royalty or similar payment the seller shall pay the other party a royalty of
twenty-five percent (25%) of such payments. GPS has assigned its rights under
the GPS Agreement to Valera Pharmaceuticals (formerly known as Hydro-Med
Sciences, Inc.) (Valera). An aggregate of $29,132 was accrued and unpaid as of
December 31, 2004. This amount is adequate to cover any royalties that might be
payable through that date. For the years ended December 31, 2004, 2003, and
2002, the Company has accrued royalty expenses of approximately $36,331, $0, and
$0, respectively. No royalty expenses were required in 2003 and 2002 as the
definition of applicable products was changed creating a surplus accrual. The
Company has not received any royalty payments, or been advised of any sales that
would entitle it to royalty payments.
Limited Liability Partnership
In August 2004, The Company established Hydron Royalty Partners, LLLP, a
limited liability limited partnership, to fund existing royalty obligations in
consideration for the right to receive future royalty receipts from Valera
Pharmaceuticals, Inc. Hydron Technologies, Inc., the general partner, assigned
its rights in the Valera Agreement to the Partnership. The Partnership assumed
the existing liability for prior period royalties ($127,984) and will annually
pay the first $30,000 of any future royalties due to Valera through 2008 in
return for the right to receive any future royalties that may be due from Valera
on their new products. The Company, as general partner, holds 50.001% of the
partnership interests, and the limited partnership interests represent in the
aggregate the remaining 49.999%.
10
Item 1. Business (continued)
Inventory
The Company did not have any backorder of firm booked orders as of
December 31, 2004 and generally delivers its orders within two weeks of the date
orders are booked. Although the Company's business in not seasonal, orders
placed by Hydron's private label customers and television retailers fluctuate on
a monthly and quarterly basis. Orders placed by the Company's Catalog customers
are generally shipped within two business days of the placement of the order.
Most items can be produced within a 90-day period. Finished good inventory
will average between 6 - 12 months of sales. Packaging components must be
printed in larger quantities and the level of those types of items may exceed 12
months of sales. The inventory level of the Hydron polymer exceeds several
years' supply and it is stored in two locations to ensure availability.
Government Regulation
The Company's oxygenation process uses pure oxygen, which is a natural
substance and is not controlled. However, the containers, devices used, and the
handling of oxygen require the Food and Drug Administration's approval (FDA).
The Company complies with the Federal Food, Drug and Cosmetic Act ("FDC Act")
and must comply with the labeling requirements of the FDC Act, the Fair
Packaging and Labeling Act ("FPL Act"), and the regulations thereunder. Many
products and applications that are derived from Hydron's oxygenation technology
will be considered medical in nature and FDA approval will be required for this
area. New skin care products and most of the Company's existing products are
"cosmetics" as that term is defined under the FDC Act. Some of the Company's
products (i.e. its topical analgesic and products that contain a sunscreen or
Triclosan) are also classified as over-the-counter drugs.
Additional regulatory requirements for existing products include certain
labeling requirements, registration of the manufacturer and semi-annual update
of the drug list. Management believes that it is in compliance with these
requirements and that it faces no material costs associated with such
compliance.
Competition
The skin care business is characterized by vigorous competition throughout
the world. Product recognition, quality, performance and price have significant
influence on customers' choices among competing products and brands.
Advertising, promotion, merchandising, the pace and timing of new product
introductions, and line extensions also have a significant impact on the
consumer buying decisions. The Company competes against a number of marketers of
skin care products, many of which have substantially greater resources than the
Company. Although the Company is in competition with all skin care brands,
direct competition in electronic retailing and catalog sales includes Principal
Secret, ProActiv, Physician's Advice, Susan Lucci, Signature Club A, Marilyn
Miglin, Dr. Graff, and Serious Skin Care.
11
Item 1. Business (continued)
Seasonality
The Company's results of operations are not subject to seasonal
fluctuations.
Employees
The Company satisfies its human resource needs utilizing an outsourcing
firm that provides all administrative services relating to payroll, personnel
and employee benefits. Management continues to hire, fire, set pay rates and
supervise its staff. This arrangement enables the Company to reduce its
administrative and benefits costs relating to employees. The Company, as of
December 31, 2004, had seven full time positions.
Item 2. Properties
The Company maintains its offices at 2201 West Sample Road, Building 9,
Suite 7B, Pompano Beach, Florida 33073. The lease on this office space (3,750
square feet) expires August 31, 2005 and requires a monthly rent of
approximately $5,588, including taxes and common area expenses. The Company
expects to renew the lease on a short-term basis. Other properties are available
at comparable monthly rental, if required.
Item 3. Legal Proceedings
The Company is not a party to, and its property is not the subject of, any
material pending legal proceedings.
12
Item 4. Submission of Matters to a Vote of Security Holders
A Meeting of the Shareholders of the Company was held on November 15,
2004, in Boca Raton, Florida (the "Meeting"). At the Meeting, the shareholders
of the Company voted on proposals to (i) elect a Board of four directors to
serve until the Company`s next meeting of shareholders and until their
successors are elected and qualified; (ii) approve the Company's 2003 Stock
Plan; and (iii) to ratify the appointment of DaszkalBolton LLP as the
independent auditors of the Company for the year ended December 31,2004. The
results of the voting appointed the following Directors:
Richard Banakus
Joshua Rochlin
Karen Gray
Ronald J. Saul
The Shareholders also approved the adoption of the Company's 2003 Stock
Plan and ratified the Audit Committee's selection of DaszkalBolton LLP as the
Company's independent Certified Public Accountants for the year ended December
31, 2004.
13
PART II
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities
Market Information
The Company's Common Stock is quoted on the OTC Bulletin Board, a
regulated quotation service for over-the-counter securities not listed or traded
on NASDAQ or a national securities exchange, under the symbol HTEC.OB. The
following tables indicate the high and low closing prices for the Company's
Common Stock as reported by the OTC Bulletin Board.
High Low
Closing Closing
Price Price
------- -------
2004
--------------
Fourth Quarter $0.45 $0.16
Third Quarter 0.42 0.27
Second Quarter 0.80 0.37
First Quarter 0.82 0.57
2003
-------------
Fourth Quarter $0.80 $0.42
Third Quarter 0.80 0.57
Second Quarter 0.53 0.20
First Quarter 0.39 0.20
As of September 16, 2004, there were approximately 4,268 shareholders of
record of the Company's Common Stock. The number of shareholders of record will
decline as the Company's transfer agent has notified the Company of its intent
to transfer shares, held in the name of shareholders that it has not been able
to locate, to the proper authorities in compliance with state law requirements
relating to unclaimed property.
Dividends and Dividend Policy
The Company does not contemplate paying dividends in the near-term. The
Board of Directors will determine the payment of dividends in the future in
light of conditions then existing, including the Company's earnings and
financial condition.
Recent Sales of Unregistered Securities
On December 10, 2002, the Company completed the sale in a non-broker
transaction to accredited investors of 1,750,000 units, comprised of one share
of Common Stock and one option to purchase one share of Common Stock at an
exercise price of $.20 per share for a three-year period commencing on the date
of issuance. The purchase price for each unit was $.20 resulting in gross
proceeds to the Company of $350,000.
14
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities (continued)
In addition, on November 14, 2003, the Company completed the sale in a
non-brokered transaction to accredited investors of 2,230,000 units, comprised
of one share of its Common Stock and one common stock purchase warrant
exercisable for one share of Common Stock at an exercise price of $1 per share
for a five-year period commencing on the date of issuance. The purchase price
for each unit was $.50 resulting in gross proceeds to the Company of $1,105,000.
In each case, the Company did not register the sale of the units and the
component shares of Common Stock, and options and warrants or the shares of
Common Stock issuable upon exercise of the warrants and options under the
Securities Act in reliance on the exemption from registration provided by Rule
506 of Regulation D and Section 4(2) of the Securities Act.
In connection with the sales of these units, the Company agreed to
register the shares of Common Stock and the shares of Common Stock issuable upon
exercise of the warrants and options included in the units. The Company prepared
the necessary registration statement and received notice from the Security and
Exchange Commission that it was declared effective on July 22, 2004.
The Company has used the proceeds from the sales of these units primarily
for certain R&D and other expenses relating to the development of its
oxygenation technology, and general working capital requirements.
Equity Compensation Plan Information
The following table summarizes share information about the Company's
equity compensation plans, including the company's Stock Option Plan ("the
Plan") and non-plan equity compensation agreements as of December 31, 2004:
15
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities (continued)
Number of Securities Number of Securities
to be Issued Weighted-Average Remaining Available for
Upon Exercise of Exercise Price of Future Issuance Under
Outstanding Options, Outstanding Options, Equity Compensation
Plan Category Warrants and Rights Warrants and Rights Plans
- --------------------------------- --------------------------------- --------------------------- -------------------------------
Equity compensation plans
approved by security holders 1,340,500 $ 0.39 (1)
Equity Compensation
plans not approved
by security holders 25,000 $ 0.22 (1)
---------------
Total 1,365,500 $ 0.39
===============
(1) The 2003 Stock Plan was approved at the November 15, 2004 sharteholders'
meeting. The aggregate number of shares that may be issued under the Plan
can not exceed 15% of the total outstanding shares. As of December 31,
2004, the number of Securities for future issuance under the 2003 Stock
Plan was 381,550 and 58,600 for all previous plans.
Equity Compensation Plans Approved by Shareholders
The 1993 Nonemployee Director Stock Option Plan ("1993 Plan") was adopted
by the Board of Directors on December 22, 1993, approved by the shareholders on
July 19, 1994 and approved, as amended, by the shareholders on December 17,
1997. The purpose of the 1993 Plan is to assist the Company in attracting and
retaining key directors who are responsible for continuing the growth and
success of the Company. No options were granted under the 1993 Plan during the
year ended December 31, 2004.
On November 10, 1997, the Board of Directors of the Company adopted the
1997 Nonemployee Director Stock Option Plan ("1997 Plan"). This plan was
approved by the shareholders on December 17, 1997. The purpose of the 1997 Plan
is to assist the Company in attracting and retaining experienced and
knowledgeable nonemployee directors who will continue to work for the best
interests of the Company.
The 1997 Plan provides nonqualified stock options for nonemployee
directors to purchase an aggregate of 100,000 shares of Common Stock, with
grants of options to purchase 2,000 shares to each nonemployee director on
October 1, 1997, grants of options to purchase 2,000 shares on each May 1st
thereafter (starting in 1999), and grants of options to purchase 2,000 shares
upon election or appointment of any new non-employee directors. The options are
not exercisable for a one-year period and are to be granted at an exercise price
equal to the average fair market value of the Common Stock during the ten
business days preceding the day of the grant of the option.
The 1997 Plan also provides nonqualified stock options for nonemployee
directors who serve on committees of the Board of Directors. The options are not
exercisable for a one-year period and are to be granted at an exercise price
equal to the average fair market value of the Common Stock during the ten
business days preceding the day of the grant of the option. No options were
granted under this provision of the 1997 Plan during the year ended December 31,
2004.
16
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities (continued)
During August 1999, the Company agreed to grant an option to purchase
18,000 shares of the Company`s common stock to each of the five individuals
comprising the Board of Directors, subject to shareholders' approval at the next
annual meeting at an exercise price of $.64065 per share.
In August 2001, the Company agreed to increase the options granted to
Board members each year. Subject to shareholders approval, the Company agreed to
grant options to purchase a total of 20,000 shares of the Company's common stock
to each of the five individuals comprising the Board of Director, beginning with
the calendar year 2000. Each Board Member will receive options to purchase
18,000 shares of common stock at an exercise price of $.20157 for their service
in 2000 and options to purchase 20,000 shares of common stock at an exercise
price of $.4275 for their service in 2001, $.3155 for their services in 2002,
$.2430 for their services in 2003, and $.5945 for services in 2004. On November
15, 2004, the Shareholders' approved a new 2003 Stock Plan that ratified these
actions by the Board of Directors.
On November 19, 2003, the Board approved, subject to shareholder approval,
the 2003 Stock Plan (the "2003 Plan"). The shareholders approved this plan on
November 15, 2004. The 2003 Plan permits the grant of nonqualified and incentive
stock options, as well as restricted stock purchases. The form of the equity is
left up to the discretion of the committee of the Board (or the Board, if no
committee) at the time of each grant. This 2003 Plan is designed to consolidate
and replace two Stock Option Plans, which have expired; the 1993 Stock Option
Plan and the 1997 Non-employee Director Stock Option Plan. The purpose of the
2003 Plan is to assist the Company in attracting, retaining, and motivating key
employees, officers, directors, and consultants by offering selected individuals
an opportunity to acquire a proprietary interest in the success of the Company.
Equity Compensation Plans Not Approved by Shareholders
The Company has agreements with several consultants who provide financial,
business, and technical advice to the Company in connection with the research,
development, marketing and promotion of its products and other matters. As part
of their compensation, these consultants were granted warrants and nonqualified
stock options to purchase shares of the Company's common stock at prices
representing the fair market value of the shares at the date of grant.
17
Item 6. Selected Financial Data
Years Ended December 31,
2004 2003 2002 2001 2000
----------- ----------- ----------- ----------- -----------
Net Sales $ 1,185,416 $ 1,219,710 $ 1,671,641 $ 2,132,717 $ 2,203,847
Operating (Loss) (874,437) (835,294) (905,868) (748,243) (946,771)
Interest (expense) - net 3,749 (101,562) 1,028 9,198 20,945
Net (Loss) (855,879) (936,856) (904,840) (758,696) (923,632)
Basic & Diluted Earnings
(Loss) per Common Share (0.09) (0.13) (0.17) (0.15) (0.19)
Total Assets 1,120,422 1,743,087 1,468,549 2,036,182 2,800,515
Total Shareholders' Equity 393,775 1,168,500 887,606 1,382,944 2,141,640
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations
Overview
In November 2003, the Company was granted a patent on its new oxygenation
technology that provides a method for delivering oxygen into the skin and tissue
at depths considered medically therapeutic. This unique technology utilizes
topical applications, eliminating reliance on the blood steam. Preliminary
research was conducted at the University of Massachusetts and Florida Atlantic
University and the process to obtain FDA approval was initiated. Management
plans to research additional medical applications once Hydron obtains FDA
approval.
The Company raised $1.1 million in December 2003 in a non-brokered private
placement exempt from registration under the Securities Act to fund the initial
research and initiate the lengthy FDA approval process. As research results
begin to quantify the broad applications of this technology and the FDA hurdles
are passed, Management anticipates that Hydron will attract key strategic
partners and new investment money will become available. Management also expects
that product development will accelerate in medical areas such as wound and burn
treatment, and skin care applications such as scar reduction, acne, and diaper
rash treatment, oral health, etc.
In 2002 the Company virtually eliminated sales made through television
retailers, having terminated the exclusive relationship with HSN in late 2001,
and as revenues derived from resales by QVC to prior customers declined.
Management expects that in 2005 and beyond, an increasing portion of the
Company's skin care sales will be generated from direct marketing utilizing
direct response mail, the Company's catalog, and web site, and licensing
arrangements. Management also expects that the Company will generate an
increasing portion of its revenues from sales made through private label
partners and will look for other opportunities to sell the Company's products
through similar arrangements. Management anticipates introducing new cosmetic
products based on its oxygenation technology, which it believes will open doors
for new distribution. However, the types and timing of the introduction of new
cosmetic products will depend upon, the results of further clinical testing.
18
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
In August 2004, Hydron Technologies, Inc. (Hydron), as general partner,
formed Hydron Royalty Partners, LLLP (Partners) a Limited Liability Limited
Partnership for the purpose of funding existing royalty obligations and a
portion of future royalty obligations in consideration of sharing future royalty
income that may arise from Hydron's agreement with Valera Pharmaceuticals, Inc.
(Valera). Partners has completed a non-brokered private placement of Limited
Partnership Interest to ten accredited investors including Hydron's Chairman,
Richard Banakus and a Hydron Director, Ronald J. Saul. Each limited partner
invested $30,000 or an aggregate of $300,000 for a 49.999% interest of Partners.
The establishment of the Partners allowed Hydron to meet its current and future
royalty obligations and retain the possibility of a significant royalty income
stream opportunity.
The Company's current revenue base will not support the overhead cost of a
public company and/or the research and development needed to advance its
oxygenation technology through the FDA approval process. Management believes
that the Company's survival and success is dependent upon one or more of the
following events: its ability to merge with another company that has
distribution channels and sales volume into retail markets; reduce overhead
costs associated with a public company by forming a new private entity and
transferring the operating assets to it and selling the public shell; sell one
or more of the Company's non-operating assets; attract additional capital.
Results of Operations - 2004 versus 2003
Total net sales for 2004 were $1,185,416, a decrease of $34,294 or 2.8%
from net sales of $1,219,710 for the year ended December 31, 2003. Skin care
product net sales for 2004 were $1,046,452, a decrease of $18,691 or 1.8% from
sales of $1,065,143 in 2003. Professional product net sales for 2004 were
$18,522, an increase of $205 or 1.1% from sales of $18,317 in 2003. Freight
revenues for 2004 were $118,617, a decrease of $11,207 or 8.6% from freight
revenues of $129,824 in 2003.
Skin care product sales consist primarily of catalog sales and private
label sales. During 2004, direct marketing catalog sales decreased by $163,205
or 16.6% from $982,240 in 2003 to $819,035 in 2004. Private label sales in 2004
were $227,416, an increase of $170,360 or 298.6% from private label sales of
$57,056 in 2003. These sales tend to fluctuate from year to year as purchase
orders cover more than one year's supply and every product in the line is not
purchased every year. Skin care product sales to retail stores were less than 1%
of sales in 2004 and 2003.
Professional sales consist of dental products sold to dental labs for use
in manufacturing dentures. As noted above, net sales of dental products for 2004
were $18,522, an increase of $205 or 1.1% from sales of $18,317 in 2003.
Over 98% of the Company's products are sold in the United States. The
Company sells skin care products in Australia and dental products in Spain and
Canada. These sales are not material at this time and represented 1.1% and 1.2%
of total sales for 2004 and 2003, respectively.
19
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
Cost of sales was $525,317 for 2004, a decrease of $59,869 or 10.2% from
cost of sales of $585,186 for 2003. Cost of sales was 44.3% of total sales in
2004 compared to 48.0% in 2003. The decrease in the cost of sales percentage
reflects tighter control of inventory levels and favorable inventory valuation
adjustment. Cost of sales for private label sales was in direct proportion to
the sales level. The Company monitors its inventory levels closely and
writes-down any inventory in excess of a one-year supply. Cost of sales include
charges of $59,412 in 2004 to adjust inventories to a one-year supply valued at
the lower of cost or realizable value on a FIFO basis. Similar charges for 2003
were $156,762. Cost increases are not material to catalog sales and the private
label contracts provide for a pass through of any cost increases incurred in
that segment.
The Company's overall gross profit margin increased slightly to 55.7% of
net sales for 2004 versus 52.0% for 2003. This reflects the costs discussed
above, less the relative mix of higher margin catalog sales versus lower margin
private label sales.
Royalty expenses in 2004 were $36,331 and $0 in 2003. No accrued royalty
expenses were required in 2003 as the definition of applicable products was
changed creating a surplus accrual. An aggregate of $29,132 was accrued and
unpaid as of December 31, 2004. This amount is adequate to cover any royalties
that might be payable through December 2004.
Research and development ("R&D") expenses reflect the Company's efforts to
identify new product opportunities, develop and package the products for
commercial sale, perform appropriate efficacy and safety tests, conduct consumer
panel studies and focus groups, and the costs associated with obtaining FDA
product approval. R&D expenses in 2004 were $279,965, an increase of $181,397,
or 184.0% from R&D expenses of $98,568 in 2003. This increase is due principally
to the Company's efforts in preparing the support data on its FDA oxygenation
application. The amount of R&D expenses per year varies, depending on the nature
of the development work, as well as the number and type of products under
development at such time.
Selling, general and administrative ("SG&A") expenses in 2004 were
$1,184,323, representing an increase of $6,112 or 0.5% from SG&A expenses of
$1,178,211 in 2003. Advertising and promotional expenses in 2004 were $61,631,
an increase of $9,627 or 18.5% from advertising and promotional expenses of
$52,004 in 2003. Sales commissions in 2004 were $11,290, an increase of $9,476
or 522.4% from sales commissions of $1,814 in 2003. The increased sales
commissions reflect the increase in private label sales and commission on
existing in-house orders that were paid when a broker/commission arrangement was
terminated. Professional expenses (legal and audit) were $123,451 in 2004, an
increase of $18,195 or 17.3% from the $105,256 incurred in 2003. The increase in
professional fees was costs associated with the registration statement filed in
July and the proxy statement for the shareholders meeting held November 15,
2004. Payroll expense was $441,809 in 2004, a decrease of $2,384 or 0.5% from
$444,193 in 2003. All other expenses were $546,142 for 2004, and decreased
$28,802 or 5.0% from $574,944 in 2003.
20
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
Depreciation and amortization expense was $33,917 for 2004, a decrease of
$159,122 or 82.4% from $193,039 in 2003. The decrease was primarily due to
intangible assets becoming fully amortized by mid-2003. Fully amortized
intangible assets of $5,370,000 were written off in 2003.
Net interest income was $3,749 in 2004 compared to net interest expense of
$101,562 in 2003. Interest expense for 2003 included $102,500 that represented
the fair value of stock options granted under an interest-free bridge loan
obtained from two Company Directors. The Company maintains a conservative
investment strategy with respect to its cash balances, deriving investment
income primarily from U.S. Treasury securities.
Minority interest in net loss in 2004 was $14,809 compare to $0 in 2003.
This minority interest is created from a consolidated limited liability
partnership, Hydron Royalty Partners, LLLP, established by the Company in August
2004 (see Limited Liability Partnership, Item 1. Business).
The Company had a net loss of $855,879, representing a decrease of $80,977
or 8.6% from the net loss of $936,856 for 2003, primarily as a result of the
factors discussed above.
Results of Operations - 2003 versus 2002
Total net sales for 2003 were $1,219,710, a decrease of $451,931 or 27.0%
from net sales of $1,671,641 for the year ended December 31, 2002. Skin care
products net sales for 2003 were $1,071,819, a decrease of $426,565 or 28.5%
from sales of $1,498,384 in 2002. Professional product net sales for 2003 were
$18,067, a decrease of $12,041 or 40.0% from sales of $30,108 in 2002. Freight
revenues for 2003 were $129,823, a decrease of $13,325 of 9.3% from freight
revenues of $143,149 in 2002.
Skin care product sales consist primarily of catalog sales and private
label sales. During 2003, direct marketing catalog sales decreased by $164,499
or 14.3% from $1,146,989 in 2002 to $982,490 in 2003. The Company did not
promote to historical customer lists from QVC and HSN as it did in 2002. These
activities were part of the termination agreements that expired in 2002. As a
result, the promotional costs as well as the sales dollars were below those seen
in 2002. Private label sales in 2003 were $57,056, a decrease of $74,152 or
56.5% from such sales of $131,208 in 2002. These sales tend to fluctuate from
year to year as purchase orders cover more than one year's supply, and each
product in the line is not purchased every year. In addition, new product
introductions are not necessarily made by the private label customers every
year. A new product was introduced in 2002, but not in 2003. Skin cares sales to
retail stores were less than 1% of sales in 2003. Retail store sales decreased
$194,584 or 96.8% from $201,010 in 2002 to $6,426 in 2003, reflecting minimal
follow-up orders by retail stores after heavily discounted introductory offers
in 2002.
21
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
Professional sales consist of dental products sold to dental labs for use
in manufacturing dentures. As noted above, net sales of dental products for 2003
were $18,067, a decrease of $12,041 or 40.0% from sales of $30,108 in 2002. In
2002 our customers increased their backroom stock after the Company experienced
delays in filling orders when one of the required components was discontinued.
Sales in 2003 reflect a more normal buying pattern for our existing customers.
Over 98% of the Company's products are sold in the United States. The
Company sells skin care products in Australia and dental products in Spain and
Canada. These sales are not material at this time and represented 1.2% and 1.7%
of total sales for 2003 and 2002, respectively.
Cost of sales was $585,186 for 2003, a decrease of $178,172 or 23.3% from
cost of sales of $763,358 for 2002. Cost of sales was 48.0% of total sales in
2003 compared to 45.7% in 2002. The increase in the cost of sales percentage
reflects the cost ($8,475) incurred to replace private label products that had
not sealed properly and slightly higher inventory valuation adjustments, offset
by the fact that high margin catalog sales represented a larger portion of total
sales in 2003 (80.5%) than they did in 2002 (68.5%). Cost of sales for private
label sales was in direct proportion to the sales level after taking into
account the charge for the replacement products. The Company monitors its
inventory levels closely and writes-down any inventory in excess of a one-year
supply. Cost of sales include charges of $156,762 in 2003 to adjust inventories
to a one-year supply valued at the lower of cost or realizable value on a FIFO
basis. Similar charges for 2002 were $128,893. Cost increases are not material
to catalog sales, and the private label contracts provide for a pass through of
any cost increases incurred in that segment.
The Company's overall gross profit margin decreased slightly to 52.0% of
net sales for 2003 versus 54.3% for 2002. This reflects the costs discussed
above less the relative mix of higher margin catalog sales versus lower margin
private label sales.
Royalty expenses in 2003 and 2002 were $0. No accrued royalty expenses
were required as the definition of applicable products was changed creating a
surplus accrual. An aggregate of $127,437 was accrued and unpaid as of December
31, 2003. This amount is adequate to cover any royalties that might be payable
through December 2003.
Research and development ("R&D") expenses reflect the Company's efforts to
identify new product opportunities, develop and package the products for
commercial sale, perform appropriate efficacy and safety tests, and conduct
consumer panel studies and focus groups. R&D expenses in 2003 were $98,568, an
increase of $30,311, or 44.4% from R&D expenses of $68,257 in 2002. This
increase is due principally to the Company's R&D work on its new oxygenation
technology. The amount of R&D expenses per year varies, depending on the nature
of the development work, as well as the number and type of products under
development at such time.
Selling, general and administrative ("SG&A") expenses in 2003 were
$1,178,211, representing a decrease of $251,959 or 17.6% from SG&A expenses of
$1,430,170 in 2002. Sales commissions for 2003 were $1,816, a decrease of
$55,385 or 96.8% from $57,201 in 2002. Sales commissions were primarily related
22
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
to retails sale introductions in 2002 and decreased in line with the lower
retail sales in 2003. Legal expenses were $63,504 in 2003, a decrease of $65,983
or 51.0% from the $129,487 incurred in 2002. The legal costs for 2002 included
the one-time cost associated with the Life International Products, Inc.
licensing agreement for machine technology that creates micro-bubbles in liquids
and legal costs associated with the Company's new oxygenation technology.
Payroll expense was $444,193 in 2003, a decrease of $45,647 of 9.3% from
$489,840 in 2002. This decrease was primarily due to the elimination of a
managerial position in order to control operating costs. Warehousing expense was
$37,210 in 2003, a decrease of $27,857 or 42.8% from the $65,067 incurred in
2002. This decrease reflects Management's efforts to reduce inventory levels and
streamline the product line. Promotion expense in 2003 was $52,129, a decrease
of $25,205 or 32.6% from $77,334 in 2002. This decrease was principally the
elimination of direct marketing activities to historical QVC and HSN customers.
Postage expense was $74,977 in 2003, a decrease of $14,973 of 16.6% from $89,950
in 2002. This decrease was principally the postage cost associated with the
marketing activities to QVC and HSN customers. All other expenses were $504,382
for 2003 and decreased $16,909 of 3.2% from $521,291 in 2002.
Depreciation and amortization expense was $193,039 for 2003, a decrease of
$122,685 or 38.9% from $315,724 in 2002. The decrease was primarily due to
intangible assets becoming fully amortized by mid-2003. Fully amortized
intangible assets of $5,370,000 were written off in 2003.
Net interest expense was $101,562 in 2003 compared to net interest income
of $1,028 in 2002. Interest expense for 2003 included $102,500 that represented
the fair value of stock options granted under an interest-free bridge loan
obtained from two Company Directors. The Company maintains a conservative
investment strategy with respect to its cash balances, deriving investment
income primarily from U.S. Treasury securities.
The Company had a net loss of $936,856, representing an increase of
$32,016 or 3.5% from the net loss of $904,840 for 2002, a result primarily of
the factors discussed above.
Results of Operations - 2002 versus 2001
Total net sales for 2002 were $1,671,641, a decrease of $461,076 or 21.6%,
from net sales of $2,132,717 for the year ended December 31, 2001. Skin care
products net sales for 2002 were $1,498,384, a decrease of $467,743 or 23.8%
from $1,966,127 in 2001. Professional products net sales for 2002 were $30,108,
an increase of $10,922 or 56.9% from $19,186 in 2001. Freight revenues for 2002
were $143,149, a decrease of $4,255 or 2.9% from freight revenues of $147,404 in
2001.
Skin care product sales consist of catalog sales, television retail, and
private label sales. During 2002, direct marketing catalog sales decreased
slightly by $31,263 or 2.6% from $1,178,252 in 2001 to $1,146,989. The reduction
in catalog sales resulted primarily from an increase in sales made with
promotional discounts. Television retail sales in 2002 were $19,177, a decrease
23
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
of $328,454 or 94.5% from $347,631 in 2001. The decrease reflects the
termination of the HSN agreement in late 2001, as well as declining revenues
received from repeat sales by QVC to prior purchasers of the Company's products.
Sales to television retailers represented 1.1% of the Company's sales in 2002,
down from 16.3% in 2001. Private label sales were $131,208 in 2002, a reduction
of $271,349 or 67.4% from sales of $402,557 in 2001, primarily the result of
pipeline fill shipped to the customer in the second half of 2001.
Professional sales consist of dental products sold to dental labs for use
in manufacturing dentures. Dental product sales in 2002 were $30,108, an
increase of $10,922 or 56.9% from $19,186 in 2001. This increase resulted when
customers increased their backroom stock after the Company experienced delays in
filling orders in 2002, when one of its required components was discontinued. It
took several months for the Company to certify a new manufacturer and qualify
the component for insertion in its dental product.
Over 97% of the Company's products are sold in the United States. The
Company sells skin care products in Australia and dental products in Spain and
Canada. In 2001, the Company also sold skin products to a pilot distributor in
Taiwan, but that business was not continued in 2002. International sales are not
material at this time and represented 1.7% and 2.5% of total sales for 2002 and
2001, respectively.
Cost of sales was $763,358 for 2002, a decrease of $179,302 or 19.0% from
cost of sales of $942,660 for 2001. Cost of sales was 45.7% of total sales in
2002 compared to 44.2% in 2001. The increase in the cost of sales percentage
reflects an increase in the cost of shipments to our customers that was not
passed on in the customer's billings. Shipping cost in 2002 were $174,911, an
increase of $3,731 or 2.2% from $171,180 in 2001. In 2002, 81.8% of the shipping
costs were billed to customers compare to 86.1% in 2001. The Company monitors
its inventory levels closely and writes-down any inventory in excess of one-year
supply. Cost of sales include charges of $128,893 in 2002 to adjust inventories
to one-year supply valued at the lower of cost or realizable value on a LIFO
basis. Similar charges for 2001 were $154,594. Cost increases are not material
to catalog sales and the private label contracts provide for a pass through of
any cost increases incurred in that segment.
The Company's overall gross profit margin decreased slightly to 54.3% of
net sales for 2002 versus 55.8% for 2001, as the increased shipping costs were
not reflected in the customer billings. The gross profit margin of catalog sales
decreased slightly to 80.3% in 2002 from 81.9% in 2001 as the result of the mix
of products and collections sold.
Royalty expenses in 2002 were $0, representing a decrease of $86,574 or
100%, from royalty expenses of $86,574 in 2001. No royalty expense was required
in 2002 as the definition of applicable products was changed creating a surplus
accrual. An aggregate of $127,437 was accrued and unpaid as of December 31,
2002. This amount is adequate to cover any royalties that might be payable
through December 2002.
24
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
R&D expenses reflect the Company's efforts to identify new product
opportunities, develop and package the products for commercial sale, perform
appropriate efficacy and safety tests, conduct consumer panel studies, and focus
groups. R&D expenses in 2002 were $68,257, an increase of $9,935 or 17.0%, from
R&D expenses of $58,322 in 2001. The amount of R&D expenses per year varies,
depending on the nature of the development work during each year, as well as the
number and type of products under development at such time.
SG&A expenses in 2002 were $1,430,170, representing a slight increase of
$2,054 or 0.1%, from SG&A expenses of $1,432,224 in 2001. Sales commissions for
2002 were $57,201, a substantial increase of $51,079 from $6,122 in 2001. This
increase was directly related to commission paid during the Company's 2002
promotional program to introduce its product line to several retail chains.
Employee payroll and benefits were $577,435 in 2002, an increase of $41,380 or
7.7% from $536,055 in 2001. Payroll increased 5.0% and the remaining increase
reflected the escalating cost of medical benefits. Insurance expense for 2002
was $99,880, an increase of $22,674 or 29.4% from $77,206 in 2001. This increase
is directly related to the increased cost of Directors and Officers insurance.
All other SG&A expenses in 2002 were $695,654, a decrease of $117,187 or 14.4%
from $812,841 in 2001. This decrease includes reductions in royalties, legal and
audit fees, computer technology services and travel expenses.
Depreciation and amortization in 2002 was $315,724, a decrease of $45,456
or 12.6% from $361,180 in 2001. This decrease relates to the depreciation of the
leasehold improvements associated with the Company's previous office facility.
The lease on that facility expired September 2001 and the offices were
relocated.
Interest and investment income in 2002 was $1,028, a decrease of $8,170 or
88.8%, from interest income of $9,198 in 2001, due primarily to lower cash
balances resulting from the factors discussed above. The Company maintains a
conservative investment strategy with respect to its cash balances, deriving
investment income primarily from U.S. Treasury securities.
The Company had a net loss for 2002 of $904,840, representing an increase
of $146,144 or 19.3% from the net loss of $758,696 for 2001, a result primarily
of the factors discussed above.
Liquidity and Capital Resources
The Company anticipates that present working capital balances and
internally generated funds will be sufficient to meet our working capital needs
for the next three months and maybe longer based on management decisions and
order flow. Beyond that point, it will be necessary to consummate a merger, sell
selected assets, or obtain an infusion of capital. The Company's independent
accountants issued a "going concern" opinion since the Company has incurred
significant losses over the past five years and generates a negative cash flow
on a monthly basis. The Company's working capital was approximately $457,023 at
December 31, 2004, including cash and cash equivalents of approximately
$339,679. Cash used by operating activities during the twelve months ended
December 31, 2004 was $901,006 and $42,141 was invested in equipment and
patents. This was offset by proceeds from financing activities of $318,103
25
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
The Company does not have any material debt, long-term capital leases or
long-term operating leases. The lease on the current office facility expires
August 31, 2005 and the Company expects to renew the lease on a short-term
basis. The only capital lease expires February 4, 2005 with total remaining
payments after December 31, 2004 of $770. There are no capital expenditures
under construction and no long-term commitments other than royalty payments
under an agreement with GP Strategies Corporation (See Note 5 to Financial
Statements). The Company does not have any lines of credit. There are no
purchase order commitments that exceed 90 days.
The Company completed a non-brokered private placement of 1,750,000 Units
at $.20 per Unit ($350,000), on December 10, 2002 to several accredited
investors. Each Unit is comprised of one share of common stock and one
three-year option to buy one additional common share at $.20. As of December 31,
2004 all 1,750,000 options are outstanding.
On November 14, 2003, the Company completed a non-brokered private
placement of 2,210,000 Units at $.50 per Unit ($1,105,000) to accredited
investors. Each Unit is comprised of one share of Common Stock and one five-year
warrant to buy one additional common share at $1.00. As of December 31, 2004,
all 2,210,000 warrants are outstanding.
The Company registered these outstanding shares and the 4,481,500
underlying shares of outstanding warrants/options with the Securities and
Exchange Commission effective July 22, 2004. The warrants/options are a future
source of capital for the Company and could generate up to $2,560,000 if they
are exercised.
The Company's independent accountants issued a "going concern" opinion
since the Company has incurred significant losses over the past five years and
generates a negative cash flow on a monthly basis. The ability of the Company to
continue as a going concern is dependent upon increasing sales, managing
operating expenses and obtaining additional equity financing.
Management's plan includes implementing one or more of the following
elements:
o Conducting merger negotiations with third parties that have
distribution networks in place. The synergies, combined sales, and
reduced overhead would create a solid operational foundation with a
solid financial position.
o Forming a new private entity and transferring the operating assets
to it and selling the public shell to one of the interested parties.
26
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
o Selling one or more of the non-operating assets.
o Obtaining an infusion of capital that will sustain the Company's
operation until the newly established licensing arrangements can
produce positive cash flow.
o Continuing to reduce overhead and operating cost.
There can be no assurances that Management's Plan will be successful and
the Company's actual results could differ materially. No estimate has been made
to the financial statements to account for the possibility that the plan may be
unsuccessful.
Change in Accounting Principle and New Accounting Pronouncements
In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation - Transition and Disclosure" - an amendment of FASB
Statement No. 123 "Accounting and Disclosure of Stock-Based Compensation". SFAS
No. 148 amends SFAS No. 123 to provide alternative methods of transition for a
voluntary change to the fair value based method of accounting for stock-based
employee compensation. In addition, SFAS No.148 amends the disclosure
requirements of SFAS No. 123 to require prominent disclosures in both annual
interim financial statements about the method of accounting for stock-based
employee compensation and the effect of the method used on reported results. The
disclosure requirements of SFAS No. 148 have been implemented in Note 1 and Note
9 to the accompanying financial statements, and the interim reporting
requirements were adopted in the first interim period in 2003. Management has
not determined whether the Company will undertake a change to the fair value
method in the near future. As our supplemental disclosure in Note 1 and Note 9
indicates, our adoption of the fair value provisions of SFAS No. 123 would not
have a negative effect on our Income Statements.
In January 2003, the FASB issued FASB Interpretation No. 46 ("FIN 46"),
"Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51,"
FIN 46 requires certain variable interest entities to be consolidated by the
primary beneficiary of the entity if the equity investors in the entity do not
have the characteristics of a controlling financial interest or do not have
sufficient equity at risk for the entity to finance its activities without
additional subordinated financial support from other parties. FIN 46 is
effective immediately for all new variable interest entities created or acquired
after January 31, 2003. For variable interest entities created or acquired prior
to February 1, 2003, the provisions of FIN 46 must be applied for the first
interim or annual period beginning after June 15, 2003. The adoption of FIN 46
did not have a material impact on the Company's financial position or on its
results of operations.
In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain
Financial Instruments with Characteristics of both Liabilities and Equity." SFAS
150 requires that certain financial instruments, which under previous guidance
were accounted for as equity, must now be accounted for as liabilities. The
financial instruments affected include mandatorily redeemable stock, certain
financial instruments that require or may require the issuer to buy back some of
its shares in exchange for cash or other assets and certain obligations that can
be settled with shares of stock. SFAS 150 is effective for all financial
instruments entered into or modified after May 31, 2003. Otherwise it will
become effective at the beginning of the first interim period beginning after
June 15, 2003. The Company does not anticipate that the adoption of this
statement will have any material impact on the balance sheet or statement of
operations.
27
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
In December 2003, the SEC issued SAB No. 104. SAB No. 104 revises or
rescinds portions of the interpretive guidance included in Topic 13 of the
codification of staff accounting bulletins in order to make this interpretive
guidance consistent with current authoritative accounting and auditing guidance
and SEC rules and regulations. It also rescinds the Revenue Recognition in
Financial Statements Frequently Asked Questions and Answers document issued in
conjunction with Topic 13. Selected portions of that document have been
incorporated into Topic 13. The adoption of SAB No. 104 did not have a material
impact on the Company's financial position, results of operations or cash flows.
In July 2004, the Emerging Issues Task Force ("EITF") published its
consensus on Issue No. 03-1, "The Meaning of Other-Than-Temporary Impairment and
its Application to Certain Investments." EITF Issue No. 03-1 addresses the
meaning of other than temporary impairment and its application to debt and
equity securities within the scope of SFAS No. 115, certain debt and equity
securities within the scope of SFAS No. 124, and equity securities that are not
subject to the scope of SFAS No. 115 and accounted for under the equity method.
In September 2004, the FASB issued FASB Staff Position ("FSP") EITF Issue No.
03-1-1, which delays the effect date for the recognition and measurement
guidance in EITF Issue No. 03-1. In addition, the FASB has issued a proposed FSP
to consider whether further application guidance is necessary for securities
analyzed for impairment under EITF issue No. 03-1. The Company continues to
assess the potential impact that the adoption of the proposed FSP could have on
our financial statements.
In December 2004, the FASB issued SFAS No. 123 (Revised 2004),
"Share-Based Payment," that addresses the accounting for share-based payment
transactions in which a Company receives employee services in exchange for (a)
equity instruments of the Company or (b) liabilities that are based on the fair
value of the Company's equity instruments or that may be settled by the issuance
of such equity instruments. SFAS No. 123R addresses all forms of share-based
payment awards, including shares issued under employee stock purchase plans,
stock options, restricted stock and stock appreciation rights. SFAS No. 123R
eliminates the ability to account for share-based compensation transactions
using APB Opinion No. 25, "Accounting for Stock Issued to Employees", that was
provided in Statement 123 as originally issued. Under SFAS No. 123R companies
are required to record compensation expense for all share based payment award
transactions measured at fair value. This statement is effective for quarters
ending after June 15, 2005. The Company has not yet determined the impact of
applying the various provisions of SFAS No. 123R.
28
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
In November 2004, the FASB issued SFAS No. 151 "Inventory Costs". This
Statement amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing", to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs, and wasted material (spoilage). In addition, this Statement
requires that allocation of fixed production overhead to the costs of conversion
be based on the normal capacity of the production facilities. The provisions of
this Statement will be effective for the Company beginning with its fiscal year
ending 2005. The Company is currently evaluating the impact of this new
standard, but believes that it will not have a material impact on the Company's
financial position, results of operations or cash flows.
In December 2004, the FASB issued SFAS No. 153 "Exchanges of Non-monetary
Assets - an amendment of APB Opinion No. 29". This Statement amended APB Opinion
No. 29 to eliminate the exception for non-monetary exchanges of similar
productive assets and replaces it with a general exception for exchanges of
non-monetary assets that do not have commercial substance. A non-monetary
exchange has commercial substance if the future cash flows of the entity are
expected to change significantly as a result of the exchange. The Company is
currently evaluating the impact of this new standard, but believes that it will
not have a material impact upon the Company's financial position, results of
operations or cash flows.
Shipping and handling billings and costs have been reclassified in the
2002 financial statements to conform to the 2004 and 2003 financial statement
presentation and the provisions of Emerging Issues Task Force No. 00 -10,
"Accounting for Shipping and Handling Fees and Costs". These reclassifications
have no effect on reported net income. In 2002, the Company reclassified
$143,149 of shipping fees to net sales and $174,911 to cost of sales. Selling,
general and administrative expenses were reduced accordingly.
The effect of inflation has not been significant upon either the
operations or financial condition of the Company.
Cautionary Statement Regarding Forward Looking Statements
The statements contained in this Report on Form 10-K that are not purely
historical are forward looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934, including statements regarding the Company's expectations, hopes,
intentions, beliefs or strategies regarding the future, including, without
limitation, it's plans regarding distribution and marketing of its products and
the development, acquisition and marketing of new products. Forward looking
statements include the Company's liquidity, anticipated cash needs and
availability, and the anticipated expense levels under the heading "Management's
Discussion and Analysis of Financial Condition and Results of Operations." All
forward looking statements included in this document are based on information
available to the Company on the date of this report, and the Company assumes no
obligation to update any such forward looking statement. It is important to note
that the Company's actual results could differ materially from those expressed
or implied in such forward-looking statements.
29
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
Application of Critical Accounting Estimates
The preparation of financial statements requires management to make
estimates and judgments that affect the reported amounts of assets, liabilities,
sales and expenses, and related disclosure of contingent assets and liabilities.
On an ongoing basis, management evaluates these estimates, including those
related to bad debts, inventories, investments, intangible assets, income taxes,
restructuring, and contingencies and litigation. Management bases these
estimates on historical experience and on various other assumptions that
management believes to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets
and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates under different assumptions or conditions.
Management believes the following critical accounting estimates are
significant in preparation of our financial statements.
Allowance for Sales Returns
The Company records product sales when persuasive evidence of an
arrangement exists, shipment has occurred, the price to the buyer is fixed or
determinable, and collectibility is reasonably assured. Catalog sales are sold
on a cash basis with a 30-day guarantee. Returns have been less than $10,000
annually for the last five years. A provision is made at the time sales are
recognized for the estimated cost of product warranties. Private label sales are
sold on account and are collected in 30 to 45 days. If there is a production or
packaging problem, the Company would correct the problem and replace the product
sold. To minimize that possibility, the Company inspects all production batches
before they are packaged to insure quality, efficacy, and consistency.
Inventory Valuation
Shifting sales from one item in our product line to another or minimum
production requirements may create a situation where inventory levels of
specific items may exceed the annual sales of that item. This can create
inventory levels in excess of net realizable value. Management regularly reviews
inventory quantities on hand and, where necessary, records provisions for excess
and obsolete inventory based on either estimated forecast of product demand or
historical usage of the product. If sales do not materialize as planned or
decline below historic levels, management increases the reserve for excess
(quantities in excess of one year's sales) and obsolete inventory. This would
reduce earnings and cash flows.
30
Item 7. Management's Discussions and Analysis of Financial Condition and Results
of Operations (continued)
Packaging changes are planned far in advance in order to limit the impact
of out-dated or obsolete components. Private label customers are required to
prepay the cost of packaging materials in order to take advantage of volume
discounts and protect the Company from any sudden packaging changes.
Item 7A. Quantitative and Qualitative Disclosure About Market Risk
The Company does not have any exposure to market risk as it does not
engage in any activities with derivative financial instruments, other financial
instruments, or derivative commodity instruments, other than the temporary
investment of available cash in U.S. Treasury instruments, cash, and cash
equivalent instruments having a similar risk profile.
Item 8. Financial Statements and Supplementary Data
The Financial Statements of the Company are contained in this report
following Item 14.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
None.
Item 9A. Controls and Procedures
As of the end of the period covered by this annual report (the "Evaluation
Date"), the Company has carried out an evaluation, under the supervision and
with the participation of management, including its Chief Operating Officer and
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures pursuant to SEC Rule 13a-15(b)
under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Based upon that evaluation, the Chief Operating Officer and Chief Financial
Officer concluded that the Company's disclosure controls and procedures (as
defined in SEC Rule 13a-15(e) are effective as of the Evaluation Date.
There have been no significant changes in the Company's internal controls
or in other factors that could significantly affect internal controls subsequent
to the date that the Company carried out is evaluation.
Disclosure controls and procedures are controls and other procedures that
are designed to ensure that information required to be disclosed in the
Company's reports or submitted under the Exchange Act is recorded, processed,
summarized and reported, within the time period specified in the rules and
procedures required pursuant to the Exchange Act. Disclosure controls and
procedures, include, without limitation, controls and procedures designed to
ensure that information required to be disclosed in the Company's reports filed
under the Exchange Act is accumulated and communicated to
31
Item 9A. Controls and Procedures (continued)
management, including the company's Chief Executive Officer and Chief Financial
Officer, to allow timely decisions regarding required disclosure.
It should be noted that any system of controls, however well designed and
operated, can provide only reasonable, and not absolute, assurance that the
objectives of the system will be met. In addition, the design of any control
system is based in part upon assumptions about the likelihood of future events
and may fail to reveal information that would require disclosure if events
deviate from the assumptions made by Management.
32
PART III
Item 10. Directors and Executive Officers of the Registrant
Identification of Directors and Executive Officers
Listed below are the directors and executive officers of the Company as of
December 31, 2004:
Name Position
---- --------
Richard Banakus Director, Chairman and Interim President
Karen Gray Director
Joshua Rochlin Director
Ronald J. Saul Director
Terrence S. McGrath Chief Operating Officer
William A. Lauby Chief Financial Officer
Business Experience
Richard Banakus, age 58, has served as a director of the Company since
June 1995 and as Interim President of the Company since September 19, 1997. From
April 1991 to the present, Mr. Banakus has been a private investor with
interests in a number of privately and publicly held companies. From July 1988
through March 1991, he was managing partner of Banyan Securities, Larkspur,
California, a securities brokerage firm that he founded.
Joshua Rochlin, age 38, has served as director of the Company since
January 2000. Mr. Rochlin joined Marc Ecko Enterprises, a producer of fashion
based streetwear and accessories, in June 2004 as the Vice President, Strategy
and Special Projects. He was Senior Vice President of Business Development at
GoAmerica, a wireless Internet service provider, from 1999 to 2004. Prior to
joining GoAmerica, Mr. Rochlin was the founder and Chief Executive Officer of
MyCalendar.com, LLC from December 1998 to December 1999. He previously served as
an associate for the law firm of Rubin Baum Levin Constant & Friedman in New
York City from February 1995 to December 1998.
Karen Gray, age 46, has served as a director of the Company since December
1997 and was a consultant to the Company on marketing and communications matters
from November 1996 to December 1999. Ms. Gray has over 17 years of management
experience in marketing communications in various capacities with various
companies. From 1993 to November 1996, Ms. Gray served as Vice President,
Corporate Communications, of the Company. From June 1992 to November 1993, Ms.
Gray served as President of MarCom Associates, Inc., a marketing communications
company that she founded.
Ronald J. Saul, age 57, has served as a director of the company since
January 2003. From September 1992 to the present Mr. Saul has been a financial
consultant. From October 1985 through August 1992 Mr. Saul was the Treasurer and
Vice President of National Intergroup, a multi company holding company. From
November 1970 to
33
Item 10. Directors and Executive Officers of the Registrant (continued)
September 1985, Mr. Saul held various accounting and financial positions with
National Intergroup Inc. and its successor company National Steel Corporation.
Terrence S. McGrath, age 47, has served as Chief Operating Officer of the
Company since January 2000. Mr. McGrath has more than 20 years' marketing, brand
management and sales experience in a diverse range of consumer goods and
cosmetic categories including Procter & Gamble Toiletries Division, Noxell,
makers of Cover Girl and Noxzema products where he specialized in new category
product development; The Isaly Klondike Company where he served as Vice
President Marketing for Klondike Ice Cream; and Pioneer Products, where he
served as Vice President Marketing and Sales for Betty Crocker licensed
products.
William A. Lauby, age 61, has served as Chief Financial Officer of the
Company since March 2000. Mr. Lauby has over 20 years' experience in companies
that manufacture and market consumer products, including The Seven-Up Company
and Isaly Klondike Company. He held the position of Chief Financial Officer for
these companies as well as for a pension and welfare organization. He is a CPA,
obtaining his experience with Ernst & Young.
Director and Officer Resignations
Mr. Joshua Rochlin has resigned from the Board of Directors of Hydron
Technologies, Inc. effective March 31, 2005 due to his increased commitments at
Marc Ecko Enterprises. In addition, William A. Lauby has resigned his position
as Chief Financial Officer effective march 30, 2005 in order to pursue other
career possibilities and to be closer to his family. The Principal Accounting
Officer position will be contracted for the short term until the operational
alternatives are solidified.
Compliance with Section 16(A) of the Securities Exchange Act of 1934
The Company's officers, directors and beneficial owners of more than 10%
of any class of its equity securities registered pursuant to Section 12 of the
Securities Exchange Act of 1934 ("Reporting Persons") are required under the Act
to file reports of ownership and changes in beneficial ownership of the
Company's equity securities with the Securities and Exchange Commission. Copies
of those reports must also be furnished to the Company. Based solely on a review
of the copies of reports furnished to the Company pursuant to the Act, the
Company believes that during the year ended December 31, 2004; all filing
requirements applicable to Reporting Persons were complied with.
Item 11. Executive Compensation
The following table sets forth information for the years ended December
31, 2004, 2003 and 2002 with respect to all compensation awarded to, earned by,
or paid to the Company's Chief Executive Officer, Chief Operating Officer and
Chief Financial Officer. None of the Company's other executive officers received
salary and bonus payments in excess of $100,000 during the year ended December
31, 2004.
34
Item 11. Executive Compensation (continued)
SUMMARY COMPENSATION TABLE
Annual Compensation Long-Term Compensation
--------------------------------- ----------------------------------------------
Awards Payouts
----------------------------------------------
Securities
Name and Principal Other Annual Restricted Under- Lying LTIP All Other
Position Year Salary Bonus Compensation Stock Award(s) Options/ SARs Payouts Compensation
- ------------------------------------------------------------------------------------------------------------------------------------
Richard Banakus, Chairman 2004 $ 10,530 -- -- -- 198,500 -- --
---------------------------------------------------------------------------------------------------------
2003 $ 10,530 -- -- -- -- -- --
---------------------------------------------------------------------------------------------------------
2002 $ 6,000 -- -- -- -- -- --
- ------------------------------------------------------------------------------------------------------------------------------------
Terrence S. McGrath, COO 2004 $125,000 -- -- -- 425,000 -- --
---------------------------------------------------------------------------------------------------------
2003 $125,000 -- -- -- -- -- --
---------------------------------------------------------------------------------------------------------
2002 $125,000 -- -- -- -- -- --
- ------------------------------------------------------------------------------------------------------------------------------------
William A. Lauby, CFO 2004 $110,000 -- -- -- 225,000 -- --
---------------------------------------------------------------------------------------------------------
2003 $110,000 -- -- -- -- -- --
---------------------------------------------------------------------------------------------------------
2002 $110,000 -- -- -- -- -- --
- ------------------------------------------------------------------------------------------------------------------------------------
During 2004, the members of the Board were granted options to purchase
20,000 shares of the Company's common stock for participation on the Company's
Board of Directors and an additional 5,000 shares if they were on a Board of
Directors committee.
The Board of Directors had approved in prior years the issuance of 178,500
options to Chairman, Richard Banakus, 425,000 options to COO, Terrence S.
McGrath and 225,000 options to CFO, William A. Lauby, subject to the approval of
the 2003 Stock Plan. The shareholders at the November 15, 2004 meeting approved
the 2003 Stock Plan. Therefore theses options are reflected as being issued in
2004.
The following table sets forth certain information relating to option
exercises effected during the year ended December 31, 2004, and the value of
options held as of such date by the Company's Chief Executive Officer and all
other persons who were executive officers of the Company and its subsidiaries
for the year ended December 31, 2004. The Company does not have any outstanding
stock appreciation rights.
35
Aggregate Option Exercises for the Year Ended December 31, 2004 and Year End
Option Values
Item 11. Executive Compensation (continued)
Number of
securities underlying Value(1) of unexercised
unexercised options In-the-money options
at December 31, 2004 at December 31, 2004
Name Shares Acquired Value ($) Exercisable/ Exercisable/
On Exercise Realized(2) Unexercisable Unexercisable
Richard Banakus -0- -0- 1,875,500(3) $0/-0-
Terence S. McGrath -0- -0- 425,000 $36,000/-0-
William A. Lauby -0- -0- 225,000 $0/-0-
Employment Agreement
There were no employment contracts in 2004, 2003, and 2002.
Compensation of Directors
Employees of the Company who also serve as directors are not entitled to
any additional compensation for such service, except for Mr. Richard Banakus,
Chairman of the Board, because of his status as Interim President. The Company
does not have a written employment agreement with Mr. Banakus.
Nonemployee directors and Mr. Banakus receive an annual fee of $5,000,
accrued quarterly. During 2004, each of Messrs. Richard Banakus, Karen Gray,
Joshua Rochlin, and Ronald J. Saul earned $5,000 for their service as a
director. As of December 31, 2004, unpaid directors' fees total approximately
$81,000.
- ----------
(1) Total value of unexercised options is based upon the closing price ($0.18)
of Common Stock as reported by NASDAQ on December 30, 2004.
(2) Value realized in dollars is the amount that the shareholder is deemed to
have received as the result of the exercise of options, based upon the
difference between the fair market value of the Common Stock as reported by
NASDAQ on the date of exercise and the exercise price of the options.
(3) Includes 1,250,000 unexercised options purchased in the Company's private
placement completed December 10, 2002; 200,000 unexercised warrants purchased in
the Company's Private Placement completed November 13, 2003; and 125,000 options
received in a bridge loan agreement with the Company dated August 4, 2003; and
300,500 options received through the Company's Stock Option Plans.
36
Item 12. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
The following table sets forth information as of December 31, 2004
regarding (i) the share ownership of the Company by each person who is known to
the Company to be the record or beneficial owner of more than five percent (5%)
of the Common Stock, (ii) the share ownership of each director of the Company,
(iii) the Chief Executive Officer of the Company and each other most highly paid
executive officer of the Company who earned in excess of $100,000 during the
year ended December 31, 2004, and (iv) the share ownership of the Company of all
directors and executive officers of the Company, as a group (six persons).
Name and Address of Amount and Nature of Approximate
Beneficial Owner Beneficial Ownership Percent of Class
Richard Banakus 3,680,740(4) 32.8%
2201 W. Sample Road
Bldg. 9, Ste. 7B
Pompano Beach, FL 33073
Karen Gray 141,000(5) 1.5%
2201 W. Sample Road
Bldg. 9, Ste. 7B
Pompano Beach, FL 33073
Joshua Rochlin 140,000(6) 1.5%
2201 W. Sample Road
Bldg. 9, Ste. 7B
Pompano Beach, FL 33073
Ronald J. Saul 1,329,740(7) 13.4%
2201 W. Sample Road
Bldg. 9, Ste. 7B
Pompano Beach, FL 33073
- ----------
(4) Consists of 1,767,740 shares held directly and 1,913,000 shares issuable
upon exercise of options and warrants.
(5) Consists of 3,000 shares held directly and 138,000 shares issuable upon
exercise of options.
(6) Consists of 140,000 shares issuable upon exercise of options.
(7) Consists of 704,740 shares held directly and 625,000 shares issuable upon
exercise of options and warrants.
37
Item 12. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters (continued)
Name and Address of Amount and Nature of Approximate
Beneficial Owner Beneficial Ownership Percent of Class
Terrence S. McGrath 425,000(8) 4.4%
2201 W. Sample Road
Bldg. 9, Ste. 7B
Pompano Beach, FL 33073
William A. Lauby 226,000(9) 2.4%
2201 W. Sample Road
Bldg. 9, Ste. 7B
Pompano Beach, FL 33073
All directors and
executive officers
as a group (6 persons) 5,942,480(10) 46.5%
Item 13. Certain Relationships and Related Transactions
No applicable transactions.
- ----------
(8) Consists of 425,000 shares issuable upon exercise of options.
(9) Consists of 1,000 shares held directly and 225,000 shares issuable upon
exercise of options.
(10) Consists of 2,476,480 shares held directly and 3,466,000 shares issuable
upon exercise of options.
38
PART IV
Item 14. Principle Accountant Fees and Services
The following table sets forth the aggregate fees billed by the Company's
principal accountant, DaszkalBolton LLP.
2004 2003
--------- ---------
Audit fees $ 29,568 $ 40,199
Audit-related fees 1,150 --
Tax fees (Tax compliance and planning) 7,500 7,000
All ther fees -- --
--------- ---------
$ 38,218 $ 47,199
========= =========
Under the procedures of the Company's audit committee, prior to engagement
of the Company's auditors to provide audit services and non-audit services, the
audit committee considers whether the provisions of such services would be
compatible with maintaining the independence of the Company's principal
accountants, and has determined that the provision of such services is
compatible with such accountants' independence.
Item 15. Exhibits, Financial Statement Schedules and reports on Form 8-K
(a)(1) Financial Statements
The following financial statements required by Item 8 follow Item 14 of this
Report:
Page
Reports of Independent Certified Public Accountants 41
Financial Statements:
Balance Sheets
December 31, 2004 and 2003 42
Statements of Operations
Years ended December 31, 2004, 2003, and 2002 43
Statements of Changes in Shareholders'
Equity for the Years ended December 31, 2004, 2003, and 2002 44
Statements of Cash Flow
Years ended December 31, 2004, 2003, and 2002 45
Notes to Financial Statements 46 - 59
39
Item 15. Exhibits, Financial Statement Schedules and reports on Form 8-K
(continued)
(a)(2) All financial schedules are omitted as the required information is not
present, is not in significant amounts sufficient to require submission of the
schedules or because the information required is included in the Financial
Statements or notes thereto.
(a)(3) Exhibits
3.1 Restated Certificate of Incorporation of Dento-Med Industries, Inc.
("Dento-Med"), as filed with the Secretary of State of New York on March
4, 1981.(11v
3.2 Certificate of Amendment of the Certificate of Incorporation of Dento-Med
as filed with the Secretary of State of New York on September 7, 1984.(12)
3.3 By-laws of the Company, as amended March 17, 1988.(13
3.4 Certificate of Change of Dento-Med as filed with the Secretary of State of
New York on July 14, 1988.(12)
3.5 Certificate of Amendment of the Restated Certificate of Incorporation of
Dento-Med, as filed with the Secretary of State of New York on November
14, 1988.(14)
3.6 Certificate of Amendment of the Restated Certificate of Incorporation of
Dento-Med, as filed with the Secretary of State of New York on July 30,
1993.(15)
3.7 Certificate of Amendment of the Restated Certificate of Incorporation of
Hydron Technologies, Inc., as filed with the Secretary of State of New
York on April 10, 2002.(12)
4.1 Non-Qualified Stock Option Plan.(16)
4.2 Registration Rights Agreement dated July 11, 2002, by and between Hydron
Technologies, Inc. and Life International Products, Inc.(12
4.3 Warrant Agreement dated November 14, 2003 between Hydron Technologies,
Inc. and the parties named therein.(12)
10.1 Subscription Agreement dated November 22, 2002 between Hydron
Technologies, Inc. and the subscribers named therein.12
10.2 Subscription Agreement dated September 31, 2003 between Hydron
Technologies, Inc. and the subscribers named therein.(12)
- ----------
(11) Incorporated by reference to the Company's report on Form 10-K for the year
ended December 31, 1985.
(12) Incorporated by reference to the Company's report on Form S-3 filed
February 11, 2004.
(13) Incorporated by reference to the Company's report on Form 10-K for the year
ended December 31, 1987.
(14) Incorporated by reference to the Company's report on Form 10-K for the year
ended December 31, 1988.
(15) Incorporated by reference to the Company's report on Form 10-K for the year
ended December 31, 1993.
(16) Incorporated by reference to the Company's report on Form 10-K for the year
ended December 31, 1986.
40
Item 15. Exhibits, Financial Statement Schedules and reports on Form 8-K
(continued)
10.3 Agreement dated July 11, 2002 between Hydron Technologies, Inc. and Life
International Products, Inc.(12)
10.4 1997 Nonemployee Director Stock Option Plan.(17)
10.5 Bridge Loan Term Sheet for Interim Loans Between Hydron Technologies, Inc
and Members of the Board of Directors.(12)
10.6 2003 Stock Plan(18)
herewith).
(b) Reports on Form 8-K
-Current Report on Form 8-K, dated September 30, 2004 reporting item 8.01
Other Events; formed a Limited Liability Limited Partnership
- ----------
(17) Incorporated by reference to the Company's Definitive Proxy Statement on
Schedule 14A for the year ended December 31, 1996.
(18) Incorporated by reference to the Company's Definitive Proxy Statement for
the year ended December 31, 2003.
41
Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Hydron Technologies, Inc.
We have audited the accompanying balance sheets of Hydron Technologies,
Inc. as of December 31, 2004 and 2003, and the related statements of operations,
changes in shareholders' equity and cash flows for each of the three years in
the period ended December 31, 2004. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audit in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. The Company has
determined that it is not required to have, nor were we engaged to perform, an
audit of its internal control over financial reporting. Our audit included
consideration of internal control over financial reporting as a basis for
designing audit procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such
opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used, and significant estimates made by management, as
well as evaluating the overall financial statement presentation. We believe that
our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Hydron Technologies, Inc. at
December 31, 2004 and 2003, and the results of their operations and their cash
flows for each of the three years in the period ended December 31, 2004 in
conformity with accounting principles generally accepted in the United States of
America.
The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. The Company experienced losses from
operations in 2004, 2003 and 2002. These matters raise substantial doubt about
the Company's ability to continue as a going concern. Management has implemented
direct marketing techniques to increase the more profitable catalog sales, add
new customers, and take advantage of new channels of distribution (see Note 13
to Financial Statements). The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
/s/: DaszkalBolton LLP
- ----------------------
Boca Raton, Florida
March 23, 2005
42
HYDRON TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
December 31,
2004 2003
------------ ------------
ASSETS
Current Assets
Cash and cash equivalents $ 339,679 $ 964,723
Trade accounts receivable 9,614 10,191
Inventories 481,996 520,032
Prepaid expenses and other current assets 67,190 34,422
------------ ------------
Total current assets 898,479 1,529,368
Property and equipment, less accumulated
depreciation of $209,329 and $204,361 at
2004 and 2003, respectively 12,673 17,641
Deposits 19,587 19,587
Deferred product costs, less accumulated
amortization of $162,135 and $133,186 at
2004 and 2003, respectively 189,683 176,491
------------ ------------
Total Assets $ 1,120,422 $ 1,743,087
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable $ 90,440 $ 42,229
Loans payable 751 4,803
Royalties payable 29,132 127,437
Deferred revenues 91,180 165,164
Accrued liabilities 229,953 234,954
------------ ------------
Total current liabilities 441,456 574,587
Commitments and contingencies -- --
Minority interest in consolidated partnership 285,191 --
Shareholders' equity
Preferred stock - $.01 par value
5,000,000 shares authorized; no shares issued
or outstanding -- --
Common stock - $.01 par value
30,000,000 shares authorized; 9,320,336 shares issued and 9,310,336
shares outstanding at 2004; 9,320,336 shares issued and 9,260,136
shares
outstanding at 2003 93,203 93,203
Additional paid-in capital 20,736,049 21,086,237
Accumulated deficit (20,427,661) (19,571,782)
Treasury stock, at cost; 10,000 at 2004
and 60,200 shares at 2003 (7,816) (439,158)
------------ ------------
Total Shareholders' equity 393,775 1,168,500
------------ ------------
Total liabilities and shareholders equity $ 1,120,422 $ 1,743,087
============ ============
See accompanying notes to condensed consolidated financial statements
43
HYDRON TECHNOLOGIES, INC.
Condensed Consolidated Statement of Operations
Year ended December 31,
2004 2003 2002
----------- ----------- -----------
Net Sales $ 1,185,416 $ 1,219,710 $ 1,671,641
Cost of sales 525,317 585,186 763,358
----------- ----------- -----------
Gross profits 660,099 634,524 908,283
Expenses
Royalty expense 36,331 -- --
Research and development 279,965 98,568 68,257
Selling, general & administration 1,184,323 1,178,211 1,430,170
Depreciation & amortization 33,917 193,039 315,724
----------- ----------- -----------
Total expenses 1,534,536 1,469,818 1,814,151
----------- ----------- -----------
Operating loss (874,437) (835,294) (905,868)
Interest income (Loss) - net of interest expense 3,749 (101,562) 1,028
----------- ----------- -----------
Loss before income taxes (870,688) (936,856) (904,840)
Minority interest in net loss 14,809 -- --
Income taxes expense -- -- --
----------- ----------- -----------
Net loss $ (855,879) $ (936,856) $ (904,840)
=========== =========== ===========
Basic and diluted loss per share
Net loss per common share $ (0.09) $ (0.13) $ (0.17)
=========== =========== ===========
Weighted average shares
outstanding (basic and diluted) 9,272,789 7,340,766 5,201,369
=========== =========== ===========
See accompanying notes to condensed consolidated financial statements
44
HYDRON TECHNOLOGIES, INC.
Condensed Consolidated Statement of Shareholders' Equity
Common Stock Preferred Stock Additional Treasury
-------------------------- -------------- Paid-in Accumulated Stock Total
Shares Amount Shares Amount Capital Deficit (at cost) Equity
------------ ------------ ------ ------ ------------ ------------ ------------ ------------
Balance at December 31, 2001 5,035,336 $ 50,353 -- $ -- $ 19,501,837 $(17,730,086) $ (439,158) $ 1,382,946
Issuance of Common shares
for license agreement 325,000 3,250 -- -- 52,000 -- -- 55,250
Private placement of
common shares 1,750,000 17,500 -- -- 332,500 -- -- 350,000
Compensation expense from
stock option awards -- -- -- -- 4,250 -- -- 4,250
Net loss -- -- -- -- -- (904,840) -- (904,840)
------------ ------------ ------ ------ ------------ ------------ ------------ ------------
Balance at December 31, 2002 7,110,336 71,103 -- -- 19,890,587 (18,634,926) (439,158) 887,606
Private placement of
common shares 2,210,000 22,100 -- -- 1,082,900 -- -- 1,105,000
Compensation expense from
stock option awards -- -- -- -- 112,750 -- -- 112,750
Net loss -- -- -- -- -- (936,856) -- (936,856)
------------ ------------ ------ ------ ------------ ------------ ------------ ------------
Balance at December 31, 2003 9,320,336 93,203 -- -- 21,086,237 (19,571,782) (439,158) 1,168,500
Sale of Treasury Stock -- -- -- -- (409,188) -- 431,342 22,154
Compensation expense from
stock option awards -- -- -- -- 59,000 -- -- 59,000
Net loss -- -- -- -- -- (855,879) -- (855,879)
------------ ------------ ------ ------ ------------ ------------ ------------ ------------
Balance at December 31, 2004 9,320,336 $ 93,203 -- $ -- $ 20,736,049 $(20,427,661) $ (7,816) $ 393,775
============ ============ ====== ====== ============ ============ ============ ============
See accompanying notes to condensed consolidated financial statements
45
HYDRON TECHNOLOGIES, INC.
Condensed Consolidated Statements of Cash Flow
Year ended December 31,
Operating Activities 2004 2003 2002
----------- ----------- -----------
Net Loss $ (855,879) $ (936,856) $ (904,840)
Adjustments to reconcile net loss to
net cash used by operating activities
Minority Interest (14,809) -- --
Depreciation and amortization 33,917 193,039 315,724
Compensation expense from stock option awards 59,000 11,188 4,250
Interest expense from stock option awards -- 101,562 --
Change in operating assets and liabilities
Trade accounts receivables 577 29,809 21,444
Inventories 38,036 222,497 421,768
Prepaid expenses and other current assets (32,768) 5,585 3,443
Deposits -- 1,229 7,386
Accounts payable 48,211 (91,754) 17,424
Royalties payable (98,305) -- --
Deferred revenues (73,984) 68,774 (52,256)
Accrued liabilities (5,002) 11,821 (37,460)
----------- ----------- -----------
Net cash used by operating activities (901,006) (383,106) (203,117)
Investing activities
Capital Expenditures, net -- (15,308) --
Deferred product costs (42,141) (37,802) (22,814)
----------- ----------- -----------
Net cash used by investing activities (42,141) (53,110) (22,814)
Financing activities
Proceeds from bridge loan -- 250,000 --
Repayment of bridge loan -- (250,000) --
Proceeds from private placement of 2,210,000 shares
of Common Stock -- 1,105,000 350,000
Net cash provided from new loans payable (4,051) 4,803 --
Proceeds from sale of Treasury Stock 22,154 -- --
Increase in minority interest of consolidated partnership 300,000 -- --
----------- ----------- -----------
Net cash provided by financing activities 318,103 1,109,803 350,000
----------- ----------- -----------
Net increase (decrease) in cash and cash equivalents (625,044) 673,587 124,069
Cash and cash equivalents at beginning of period 964,723 291,136 167,067
----------- ----------- -----------
Cash and cash equivalents at end of period $ 339,679 $ 964,723 $ 291,136
=========== =========== ===========
Noncash investing and financing activities
Market value of stock issued for license agreement $ -- $ -- $ 55,250
See accompanying notes to condensed consolidated financial statements
46
Hydron Technologies, Inc.
Notes to Financial Statements
December 31, 2004, 2003, and 2002
1. Description of Business and Summary of Significant Accounting Policies
Organization of Business
Hydron(R) Technologies, Inc. (the "Company") sells consumer and
professional products, primarily in the personal care/cosmetics field. The
Company holds the exclusive license with GP Strategies Corporation (formerly
National Patent Development Corporation) ("GPS") to a Hydron(R) polymer-based
drug delivery system for topically applied, nonprescription pharmaceutical
products, which the Company intends to use to develop proprietary products or
license to third parties. The Company owns U.S. and international patents on a
method to suspend the Hydron polymer in a stable emulsion for use in personal
care/cosmetic products.
The Company is also committed to the research and development of products
and medical applications associated with its proprietary tissue oxygenation
technology. The Company owns U.S. and international patents on a method to
infuse oxygen into the skin and tissue topically without using the blood stream.
The oxygenation technology is being submitted to the Food & Drug Administration
to obtain the necessary approvals for medical applications.
Over 98% of the Company's products are sold in the United States directly
to the consumer through Catalog sales and the internet, and to private label
customers. Less than 2% of the Company's products are sold internationally
through salons and doctors' offices.
Principles of Consolidation
The consolidated financial statements include the accounts of Hydron
Technologies, Inc. and a majority owned limited liability limited partnership,
Hydron Royalty Partners, LLLP. Hydron Royalty Partners, LLLP (the "Partners")
was established in August 2004 by Hydron, the general partner, and ten limited
partners for the purpose of paying outstanding and up to $30,000 annually of
future royalties and licensing obligations in return for royalty and licensing
payments due from Valera Pharmaceuticals, Inc. The establishment of Partners
allowed Hydron to meet its current and future royalty obligations and retain the
possibility of a significant royalty income stream opportunity. All appropriate
inter-company transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires Management to make estimates and
assumptions that
47
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
affect the amounts reported in the financial statements and accompanying notes.
Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original
maturity of three months or less to be cash equivalents. The credit risk
associated with cash equivalents is considered low due to the credit quality of
the issuers of the financial instruments.
Cash and cash equivalents includes $154,180 which are covered by the
Federal Deposit Insurance Commission and $184,999 is invested in short-term
money market funds consisting of U.S. Government instruments.
Concentration of Credit Risk
Trade accounts receivable are due primarily from Reliv International, Inc.
and are usually paid to the Company within 45 days after receipt of goods. The
Company performs ongoing evaluations of its significant customers and does not
require collateral, although in some cases it requires deposits or advances.
Inventories
Inventories are valued at the lower of cost (first-in, first-out) or
market, and include finished goods, packaging and raw materials.
Long-Lived Assets
The Company reviews long-lived assets and certain identifiable intangibles
held and used for possible impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. In evaluating the fair value and future benefits of its intangible
assets, management performs an analysis of the anticipated undiscounted future
net cash flows of the individual assets over the remaining amortization period.
The Company recognizes an impairment loss if the carrying value of the asset
exceeds the expected future cash flows. As of December 31, 2004, there was no
deemed impairment of long-lived assets.
48
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
Property and Equipment
Property and equipment, consisting primarily of furniture and equipment,
is carried at cost. Depreciation is computed using the straight-line method over
the estimated useful lives of the assets, ranging from four to six years (see
Note 4).
Deferred Product Costs
Deferred product costs consist primarily of costs incurred for the
purchase and development of patents and product rights (see Note 5). The
deferred product costs are being amortized over their estimated useful lives of
five to seventeen years using the straight-line method.
Common Stock, Common Stock Options and Net Loss Per Share
When the Company issues shares of common stock in exchange for services,
an expense is recognized over the period in which the services are rendered. The
expense is based upon the fair value of such shares, in accordance with FASB
statement No. 123 using a Black-Scholes pricing model, at the date such
arrangements are consummated or authorized by the Board of Directors, with a
corresponding credit to capital.
The Company has elected to follow Accounting Principles Board (APB)
Opinion No. 25, "Accounting for Stock Issued to Employees," and related
Interpretations in accounting for its stock options and has adopted the
disclosure-only provisions of FASB Statement No. 123, "Accounting and Disclosure
of Stock-Based Compensation." Accordingly, no compensation cost has been
recognized for the Company's stock option plans.
In December 2002, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure." The Company has elected to use the
intrinsic value method of accounting for stock compensation in accordance with
APB No. 25 and related interpretations. Had the compensation expense for the
stock option plan been determined based on the fair value of the options at the
grant date consistent with the methodology prescribed under Statement of
Financial Standards No. 123, "Accounting for Stock Based Compensation," at
December 31, the Company's net income and earnings per share would have been
reduced to the proforma amounts indicated below:
49
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
Year ended December 31,
2004 2003 2002
--------- ---------- ---------
Net loss, as reported $(855,879) $ (936,856) $(904,840)
Deduct: Total stock-based employee
compensation expense determined
under fair value-based method for all
awards, net of related tax effects (134,000) -- (12,500)
--------- ---------- ---------
Pro Forma net loss $(989,879) $ (936,856) $(917,340)
========= ========== =========
Basic and diluted loss per share
As reported $ (0.09) $ (0.13) $ (0.17)
========= ========== =========
Pro forma $ (0.11) $ (0.13) $ (0.18)
========= ========== =========
Revenue Recognition
The Company recognizes revenue when
o Persuasive evidence of an arrangement exists,
o Shipment has occurred,
o Price is fixed or determinable, and
o Collectibility is reasonably assured.
Subject to these criteria, the Company recognizes revenue at the time of
shipment of the relevant merchandise. The Company offers its customers a
thirty-day warranty and estimates an allowance for sales returns based on
historical experience with product returns.
Shipping and Handling Fees
The Company follows the provisions of Emerging Issues Task Force Issue No.
00-10, "Accounting for Shipping and Handling Fees and Costs." Any amounts billed
to third-party customers for shipping and handling is included as a component of
revenue. Shipping and handling costs incurred are included as a component of
cost of sales.
50
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
Cost of Sales
Products are manufactured through third parties under contract and cost of
sales includes the cost of ingredients, packaging material, assembly and
processing costs. Inbound freight, internal transfers, and component handling
costs are charged to cost of sales. Costs associated with shipping product to
customers is included in cost of sales. The cost of warehousing finished product
that is available for sale is included in selling, general and administrative
expenses.
Research and Development Costs
Research and development expenditures, which are comprised of costs
incurred in performing research and development activities are expensed as
incurred. As of December 31, 2004, 2003, and 2002 expenses charged to Research
and Development were $279,965, $98,568, and $68,257, respectively.
Advertising
Advertising costs are expensed as incurred and are included in "Selling,
general and administrative expenses." Advertising expenses amounted to
approximately $62,000, $52,000, and $72,000 for the years ended December 31,
2004, 2003, and 2002, respectively.
Reclassifications
Shipping and handling billings and costs have been reclassified in the
2002 and 2001 financial statements to conform to the 2003 financial statement
presentation and the provisions of Emerging Issues Task Force No. 00 -10,
"Accounting for Shipping and Handling Fees and Costs". These reclassifications
have no effect on reported net income. In 2002, the Company reclassified
$143,149 of shipping fees to Net sales and $174,911 of shipping costs to cost of
sales. Selling, general, and administrative expenses were reduced accordingly.
2. Fair Value of Financial Instruments
The carrying value of cash, accounts receivables, deposits, accounts
payable, and other payables approximates fair value because of their short
maturities
51
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
3. Inventories
At December 31, 2004 and 2003, inventories consist of the following:
2004 2003
-------- --------
Finished goods $ 93,312 $ 90,443
Raw materials and components 388,684 429,589
-------- --------
$481,996 $520,032
======== ========
The Company's earnings were reduced for excess inventory by $59,412,
$156,762, and $128,893 for the years ended December 31, 2004, 2003, and 2002,
respectively.
4. Property and Equipment
At December 31, 2004 and 2003, property and equipment consisted of the
following:
2004 2003
--------- ---------
Furniture and equipment $ 222,002 $ 222,002
Less accumulated depreciation (209,329) (204,361)
--------- ---------
$ 12,673 $ 17,641
========= =========
Depreciation for the year ended December 31, 2004, 2003, and 2002 was
approximately $4,968, $7,115, and $17,926, respectively.
5. Deferred Product Costs
The Company was granted U.S. Patent No. 4,883,659, dated November 28,
1989, and U.S. Patent No. 5,039,516, dated August 13, 1991, which cover a stable
moisturizing emulsion containing an unusual emulsifying agent, as well as the
Hydron polymer and a unique combination of ingredients. These patents have
expiration dates of November 28, 2006 and August 13, 2008, respectively. During
1999 the Company was granted U.S. Patent No. 5,879,684 for its "Line Smoothing
Complex" formula. This product has been clinically shown to reduce fine lines
and wrinkles. The patent has an expiration date of April 11, 2017.
It had been determined that the Hydron(R) emulsion system also adjusts pH
on the skin to match the pH of the stratum corneum, the skin surface layer.
Therefore, the Company filed a provisional patent application related to
acid-based ingredient delivery, including acne ingredients, in February 2002
with the corresponding utility patent application and international filings in
February 2003.
52
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
5. Deferred Product Costs (continued)
At December 31, 2004 and 2003 deferred product costs consisted of the
following:
2004 2003
--------- ---------
Deferred product cost $ 351,818 $ 309,677
Less accumulated amortization (162,135) (133,186)
--------- ---------
$ 189,683 $ 176,491
========= =========
Deferred product costs are written off in the year they are fully
amortized. Fully amortized deferred product cost of $5,370,00 was written off in
2003. Amortization for the years ended December 31, 2004, 2003, and 2002 was
approximately $27,296, $185,924 and $297,798, respectively. Estimated future
amortization of intangible assets are as follows:
2005 $ 31,264
2006 31,264
2007 20,214
2008 16,667
2009 11,746
thereafter 78,531
6. Royalty Agreements
From 1976 through 1989, the Company and GP Strategies Corporation
(formerly known as National Patent Development Corporation) ("GPS") entered into
various agreements, wherein the Company obtained the exclusive worldwide rights
to market products using Hydron polymers in cosmetic and oral health fields, the
two fields in which the Company has concentrated its research and development
efforts, and to utilize the Hydron polymer as a drug release mechanism in
topically applied, nonprescription pharmaceutical products. The Hydron polymer
is one of the underlying technologies in substantially all of the Company's skin
care products. GPS has the exclusive worldwide license to market prescription
drugs and medical devices using Hydron polymers. Further, each has the right to
exploit products with Hydron polymers not in the other's exclusive fields.
53
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
6. Royalty Agreements (continued)
Under the terms of the GPS Agreement, the Company and GPS are each
required to pay to the other a royalty of five percent (5%) of their respective
net sales of Hydron polymer products, except for sales of certain specified
non-prescription drug products, utilizing the Hydron polymer as an active
ingredient to third parties. Where the seller receives an up-front license fee,
royalty or similar payment the seller shall pay the other party a royalty of
twenty-five percent (25%) of such payments. GPS has assigned its rights under
the GPS Agreement to Valera Pharmaceuticals (formerly known as Hydro-Med
Sciences, Inc.) (Valera).
The Company and Valera were discussing possible ways to simplify the GPS
Agreement in 2004 but were unable to reach agreement. As a result, the Company
assigned its rights under the GPS Agreement to Hydron Royalty Partners, LLLP, a
newly created limited liability partnership with the Company as the "General
Partner." The partnership assumed the existing liability for prior period
royalties ($127,984) and will annually pay the first $30,000 of any royalties
due to GPS and, in return, will receive any future royalties from Valera.
An aggregate of $29,132 was accrued and unpaid as of December 31, 2004.
This amount is adequate to cover any royalties that might be payable through
December 2004. For the years ended December 31, 2004, 2003, and 2002, the
Company's Statement of Operations has accrued royalty expenses of approximately
$36,000, $0 and $0, respectively. No accrued royalty expense was required in
2003 and 2002 as the definition of applicable products was changed creating a
surplus accrual. The Company has not received any royalty payments, or been
advised of any sales that would entitle us to royalty payments.
7. Accrued Liabilities
Accrued liabilities represent expenses that apply to the reported period
and have not been billed by the provider or paid by the Company. At December 31,
2004 and 2003, accrued liabilities consisted of the following:
2004 2003
-------- --------
Dividends payable $ 83,163 $ 83,163
Director fee payable 81,016 65,012
Professional fees 40,754 29,712
Other 25,020 57,067
-------- --------
$229,953 $234,954
======== ========
54
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
8. Income Taxes
The Company accounts for income taxes under FASB Statement No. 109,
"Accounting for Income Taxes" (FASB 109). Deferred income tax assets and
liabilities are determined based upon differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax
rates and laws that will be in effect when the differences are expected to
reverse. There has been no income tax expense during the three years ended
December 31, 2004.
Deferred income taxes reflect the net tax effect of temporary differences
between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of
the Company's net deferred income taxes are as follows:
2004 2003 2002
----------- ----------- -----------
Net operating loss carryforwards $ 8,404,000 $ 8,015,000 $ 7,890,000
Tax credit carry forwards 180,000 180,000 180,000
Other 202,000 215,000 230,000
----------- ----------- -----------
Deferred tax assets 8,786,000 8,410,000 8,300,000
Less valuation allowance (8,786,000) (8,410,000) (8,300,000)
----------- ----------- -----------
Total net deferred taxes $ -- $ -- $ --
=========== =========== ===========
FASB 109 requires a valuation allowance to reduce the deferred tax assets
reported if, based on the weight of the evidence, it is more likely than not
that some portion or all of the deferred tax assets will not be realized. After
consideration of all the evidence, both positive and negative, Management has
determined that an $8,786,000 valuation allowance at December 31, 2004 is
necessary to reduce the deferred tax assets to the amount that will more likely
than not be realized. The valuation allowance increased by $376,000, $110,000,
and $161,000 in 2004, 2003, and 2002, respectively.
As of December 31, 2004, the Company had an unused net operating loss
carryforward of approximately $22,116,170 available for use on its future
corporate income tax returns. This net operating loss carryforward begins to
expire in December 2004 through 2024. Pursuant to Sections 382 and 383 of he
Internal Revenue Code, annual use of any of the Company's net operation loss and
credit carry forwards may be limited if cumulative changes in ownership of more
than 50% occur during any three year period.
55
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
8. Income Taxes (continued)
The reconciliation of income tax rates, computed at the U.S. federal
statutory tax rates, to income tax expense is as follows:
Year ended December 31,
2004 2003 2002
------- ------- -------
Tax at U.S. statutory rates -34% -34% -34%
State income taxes, net of federal tax benefit -4% -4% -4%
Valuation allowance adjustments 38% 38% 38%
------- ------- -------
0% 0% 0%
======= ======= =======
9. Stock Options and Warrants
The number of shares of common stock reserved for issuance was 5,575,500
for December 31, 2004 and 4,521,100 for 2003. This includes 2,210,000 shares for
the private placement subscription agreements completed November 14, 2003.
1997 Nonemployee Director Stock Option Plan
During 1997, the Company adopted the 1997 Nonemployee Director Stock
Option Plan. Such plan provides grants of stock options to nonemployee directors
of the Company to purchase an aggregate of 100,000 shares of the Company's
common stock.
Each nonemployee director shall be granted an option to purchase 2,000
shares of the Company's common stock on each May 1st throughout the term of this
plan at exercise prices equal to the average of the fair market value of the
Company's common stock during the ten business days preceding the date of the
grant. In addition, each nonemployee director who sits on a committee of the
Board of Directors shall be granted an option to purchase 500 shares of the
Company's common stock under the same pricing arrangements as above. Subject to
certain exceptions, no options granted under this plan shall be exercisable
until one year after the date of grant.
During August 1999, the Company agreed to increase the annual May 1st
grant to the Board members from 2,000 to 20,000 shares of the Company`s common
stock and committee members from 500 to 5,000. These options expire five years
from the date of grant and all outstanding options are exercisable at December
31, 2004. There are no options available for grant under this plan at December
31, 2004.
56
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
9. Stock Options and Warrants (continued)
Activity with respect to these plans is as follows:
Weighted
Number of Average
Options/ Price Exercise
Warrants Per Share Price
-------- -------------- ---------
Outstanding at December 31, 2002 223,500 $0.20 to $2.42 $0.62
Stock options granted -- -- --
Stock options expired (2,000) 2.42 2.42
---------
Outstanding at December 31, 2003 221,500 0.20 to 0.92 0.56
Stock options granted 1,033,500 0.13 to 0.59 0.33
Stock options expired (39,500) 0.64 to 0.92 0.67
---------
Outstanding at December 31, 2004 1,215,500 $0.13 to $0.81 $0.37
=========
The Board of Directors had approved the issuance of 943,500 options in
prior periods subject to the adoption of a new stock plan at the November 15,
2004 shareholders' meeting. All of these options have been reflected as being
granted in 2004.
Other Options and Warrants
The Company completed a non-brokered private placement of 1,750,000 Units
at $.20 per Unit ($350,000), on December 10, 2002 to several accredited
investors. Each Unit is comprised of one share of common stock and one
three-year option to buy one additional common share at $.20. As of December 31,
2004, all 1,750,000 options are outstanding.
On November 14, 2003, the Company completed a non-brokered private
placement of 2,210,000 Units at $.50 per Unit ($1,105,000) to accredited
investors. Each Unit is comprised of one share of Common Stock and one five-year
warrant to buy one additional Common Share at $1.00. As of December 31, 2004,
all 2,210,000 warrants are outstanding.
The Company has agreements with several consultants who provide financial,
business and technical advice to the Company in connection with the research,
development, marketing and promotion of its products and other matters. As part
of their compensation, these consultants were granted warrants and nonqualified
stock options to purchase shares of the Company's common stock at prices
representing the fair market value of the shares at the date of grant. Activity
with respect to options and warrants granted to these consultants is summarized
below:
57
Weighted
Number of Average
Options/ Price Exercise
Warrants Per Share Price
-------- -------------- ---------
Outstanding at December 31, 2002 25,000 $ 0.22 $0.22
Stock options granted 25,000 0.50 0.5
---------
Outstanding at December 31, 2003 50,000 0.22 to 0.50 0.36
Stock options granted 100,000 0.66 0.66
---------
Outstanding at December 31, 2004 150,000 $0.22 to $0.66 $0.56
=========
The Company's Statement of Operations for the year ended December 31, 2004
includes $59,000 of research and development cost representing the fair value of
options granted to the Company's FDA consultant. For the year ended December 31,
2003, interest expense includes $102,500 representing the fair value of options
granted in order to obtain an interest-free bridge loan from two of the
Company's Directors. An additional $10,250 is included in Selling, general &
administrative expenses representing the fair value of options granted for
services received in the private placement offering that closed on November 13,
2003. For the year ended December 31, 2002, research and development cost
include $4,250 representing the fair value of options granted to the Company's
technical consultant.
Pro forma information regarding net income and earnings per share is
required by FASB Statement No. 123, which also requires that the information be
determined as if the Company had accounted for its stock options granted
subsequent to December 31, 1994 under the fair value method of that Statement.
The fair value for these options was estimated at the date of the grant using a
Black-Scholes option pricing model with the following weighted-average
assumptions for the years ended December 31, 2004, 2003, and 2002:
2004 2003 2002
------- ------- -------
Risk-free interest rate 4.0% 4.0% 4.5%
Expected life 5 years 5 years 5 Years
Expected volatility 106% 139% 159%
Expected dividend yield 0% 0% 0%
58
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
9. Stock Options and Warrants (continued)
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options, which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. As the Company's stock options have characteristics significantly
different than those of traded options, and because changes in the subjective
input assumptions can materially affect the fair value estimate, in Management's
opinion, the existing models do not necessarily provide a reliable single
measure of the fair value of its stock options.
There were 1,133,500 options granted during the year ended December 31,
2004 when the 2003 Stock Plan was approved at the November 15, 2004
shareholders' meeting. Approximately 943,500 of these options had been approved
in previous years by the Board of Directors subject to the shareholders' action.
There were no options granted during the years ended December 31, 2003 and 2002.
The weighted average remaining contractual life of all options outstanding at
December 31, 2004 was 2.69 years.
10. Commitments
The Company leases office space under a non-cancelable lease agreement,
which expires in August 2005. At December 31, 2004, the future minimum rental
payments due under this noncancelable lease are $30,800 for the year ending
December 31, 2005. Net rent expense was approximately $66,200, $65,300, and
$70,000 in 2004, 2003, and 2002, respectively.
11. Quarterly Financial Data (unaudited)
The Company has purchased computer equipment through a financing lease
that expires in February 2005. At December 31, 2004, the future minimum lease
payments due under this non-cancelable lease are $770 for the year ended
December 31, 2005.
First Second Third Fourth
Quarter Quarter Quarter Quarter
--------- --------- --------- ---------
Net sales $ 386,132 $ 336,098 $ 200,975 $ 262,211
Operating income (loss) (165,791) (184,808) (253,076) (270,762)
Net income (loss) (164,971) (183,966) (236,686) (270,256)
Income (loss) per share $ (0.02) $ (0.02) $ (0.03) $ (0.02)
59
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
12. Subsequent Event
On January 25, 2005, the Board of Directors, by unanimous consent
re-authorized the issuance of 743,500 stock options from the 2003 Stock Plan to
Directors and Officers of the Company. Since the original approval date was more
than 12 months before the shareholder adoption of the 2003 Stock Plan, the
options had to be re-authorized to include them under the plan.
13. Management's Plan
The Company has incurred significant losses over the past five years and
generates a negative cash flow on a monthly basis. The ability of the Company to
continue as a going concern is dependent upon increasing sales, managing
operating expenses and obtaining additional equity financing.
Management's plan includes implementing one or more of the following
elements:
o Conducting merger negotiations with third parties that have
distribution networks in place. The synergies, combined sales, and
reduced overhead would create a solid operational foundation with a
solid financial position.
o Forming a new private entity and transferring the operating assets
to it and selling the public shell to one of the interested parties.
o Selling one or more of the non-operating assets.
o Obtaining an infusion of capital that will sustain the Company's
operation until the newly established licensing arrangements can
produce positive cash flow.
o Continuing to reduce overhead and operating cost.
There can be no assurances that Management's Plan will be successful and
the Company's actual results could differ materially. No adjustments have been
made to the financial statements to account for the possibility that the plan
may be unsuccessful.
60
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Hydron Technologies, Inc.
(Registrant)
By /s/: Richard Banakus
-------------------------------
Richard Banakus, Interim President
Date: March 29, 2005
Pursuant to the requirements of the Securities Exchange Act of 1934, this
Report has been signed below by the following persons on behalf of the
Registrant in the capacities and on the dates indicated:
61
Exhibit Index Index #
Certification of Chief Executive Officer Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002 and Item 307 of
Regulation S-K 31.1
Certification of Chief Operating Officer Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002 and Item 307 of
Regulation S-K 31.2
Certification of Chief Financial Officer Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002 and Item 307 of
Regulation S-K 31.3
Certification Pursuant to 18 U.S.C, Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.1
Certification Pursuant to 18 U.S.C, Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2
Certification Pursuant to 18 U.S.C, Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.3
62